Treatment compositions having modified amino acid dimers

Abstract

Treatment compositions comprising modified amino acid dimer compounds that may be useful for delivering specific benefit agents such as perfume raw materials or antimicrobial agents. Methods of making and using such compounds and compositions. Related precursor compounds and premix compositions.

Description

[Technical Field]

[0001] The present disclosure relates to treatment compositions comprising modified amino acid dimer compounds that may be useful for delivering specific benefit agents, such as perfume raw materials or antimicrobial agents. The present disclosure also relates to methods for making and using such compounds and compositions. The present disclosure also relates to related precursor compounds and premix compositions. [Background technology]

[0002] Many treatment compositions, such as those suitable for treating fabrics, contain various benefit agents, such as perfumes, that provide benefits in the end use of the product. Many of these benefit agents are intended to be deposited on target surfaces, such as fabrics. Therefore, it is useful and desirable to increase the deposition efficiency of such benefit agents, as well as their release profile.

[0003] While deposition of such benefit agents can be advantageously facilitated by deposition aids and / or carrier materials, several factors play a role in the selection of suitable materials. For example, the selected materials must provide an improved deposition profile compared to the benefit agents they are intended to deliver, which is particularly challenging in aqueous processing environments such as the wash and / or rinse cycles of an automatic washing machine. For sustainability reasons, it may be desirable for such materials to be naturally derived and / or biodegradable. In addition, it may be desirable for such materials to have suitable loading efficiencies of the delivered benefit agents and appropriate release rates of the deposited benefit agents. Furthermore, it may be desirable for such materials to be able to interact with a wide range of benefit agents and / or be conveniently incorporated into product formulations in a variety of ways. Summary of the Invention [Problem to be solved by the invention]

[0004] Thus, there is a need for improved ingredients in treatment compositions that can efficiently deposit and release benefit agents onto target surfaces, particularly in aqueous environments, and more preferably, such ingredients are derived (at least in part) from naturally occurring materials. [Means for solving the problem]

[0005] The present disclosure relates to treatment compositions comprising modified amino acid dimer compounds that may be useful for delivering certain benefit agents.

[0006] For example, the present disclosure relates to a treatment composition comprising a treatment aid and a modified amino acid dimer compound, the dimer compound comprising two amino acid moieties covalently bonded by a linking group, each amino acid moiety comprising a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom, at least one of the two amino acid moieties comprising one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, the heteroatom being bonded directly to the carbon of the carbonyl group of the amino acid moiety, the linking group being a divalent moiety bonded to a carbon atom of the carbon backbone of each amino acid moiety, the linking group being free of peptide bonds, and preferably each of the backbone carbon atoms bonded to the linking group being further bonded directly to a nitrogen atom of a respective amino acid moiety, at least one amino acid moiety comprising an organic moiety covalently bonded to the nitrogen atom of the amino acid moiety, the organic moiety comprising a benefit agent residue that can be cleaved to release a benefit agent, the benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof.

[0007] The present disclosure also relates to a processing composition comprising a processing aid and a modified amino acid dimer compound, wherein the modified amino acid dimer compound has Formula I:

[0008] [ka] wherein L is a linking group comprising 1 to 18 chain atoms, the linking group does not comprise a peptide bond, and preferably the chain atoms are selected from carbon atoms, oxygen atoms, nitrogen atoms, sulfur atoms, or combinations thereof; each Q is independently selected from a carbon-containing core comprising 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom; each G is independently selected from -O-, -N(R 6 )-, or -S-, preferably each G group is the same; R 6 is, if present, selected from —H or a monovalent moiety having a molecular weight of about 15 to about 255 Da, preferably R 6 is a monovalent moiety having a molecular weight of about 15 to about 142 Da, more preferably about 15 to about 30 Da, and each R 3 are independently selected from H, X, or a monovalent moiety having a molecular weight of about 15 to about 881 Da, preferably a monovalent moiety having a molecular weight of about 43 to about 255 Da, and X is a suitable charge-balancing counterion, provided that at least one R 3 is a monovalent part, and R 3 and, if present, R 6 and the monovalent moieties together comprise a total of 5 to 34 chain atoms, preferably about 8 to about 18 chain atoms, more preferably about 8 to about 14 chain atoms, each A group being a monovalent nitrogen-containing moiety, and at least one A group comprising a benefit agent residue that can be cleaved to release a benefit agent, wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof.

[0009] The present disclosure further relates to the modified amino acid dimer compounds described herein.

[0010] The present disclosure further provides modified amino acid dimer precursor compounds, such as those represented by Formula I':

[0011] [ka] (Wherein L, Q, G, and R 3is as defined above, and each A is (a) H2N-, or (b) HG'(J) d N(H)—, where G′, J, and d are monovalent nitrogen-containing moieties independently selected from the group consisting of: N(H)—, and G′, J, and d are as defined above.

[0012] The present disclosure further relates to a premix composition comprising a modified amino acid dimer precursor compound, a benefit agent, and optionally water, wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof. The premix may further preferably comprise a non-aqueous solvent, more preferably a hydroxyl-containing solvent, and even more preferably ethanol.

[0013] The present disclosure further relates to a method for producing a treatment composition, the method comprising at least one of the following steps: (a) combining a modified amino acid dimer compound with an auxiliary component, preferably where the auxiliary component is part of a base composition; (b) combining a premix composition according to claim 29 with an auxiliary component, preferably where the auxiliary component is part of the base composition; and (c) combining a modified amino acid dimer precursor compound, a benefit agent, and an auxiliary component, preferably where the auxiliary component is part of the base composition and the modified amino acid dimer compound and the benefit agent are each added as separate inputs to the base composition.

[0014] The present disclosure further relates to a method for treating an article or surface, the method comprising treating the article or surface with a treatment composition according to any one of claims 1 to 26, optionally in the presence of water, and optionally further comprising rinsing and / or drying the article or surface. DETAILED DESCRIPTION OF THE INVENTION

[0015] The present disclosure relates to treatment compositions comprising modified amino acid dimer compounds that enhance the deposition and release of benefit agents. Accordingly, the amino acid dimer compounds of the present disclosure may be considered "pro-benefit agent compounds," such as pro-fragrance compounds.

[0016] Modified amino acid dimeric compounds (as used herein, "dimeric compounds" or more simply "dimers") of the present disclosure comprise two amino acid moieties covalently linked to one another, for example, by a linking group. The linking group may be derived from one or more side groups of the amino acid moieties (e.g., when such moieties are derived from proteinogenic amino acids), or may be two respective side groups covalently linked to one another. Alternatively, the linking group may comprise a divalent moiety that links the side groups or replaces one or both of them.

[0017] Additionally, the dimeric compounds of the present disclosure contain one or more residues of benefit agents that are released over time, preferably when the dimeric compound is attached to a target surface such as a fabric. The benefit agent residue-forming moieties include aldehyde or ketone moieties that react with the amine group of the amino acid moiety. Once the bond is broken, the benefit agent is released.

[0018] Additionally, the dimeric compounds of the present disclosure contain one or more hydrophobic moieties on one or more of the carbonyl groups of the dimer, which serves to improve the adhesion profile of the compound onto target surfaces, particularly in aqueous processing environments and / or onto hydrophobic surfaces.

[0019] The dimeric compounds of the present disclosure offer more options for modification and loading efficiency compared to single amino acids.For example, a single dimeric compound may advantageously have at least two beneficial agent residues and may contain one, two, or more hydrophobic moieties.Therefore, two beneficial agent residues may be delivered with the help of a single long hydrophobic substance or by two shorter hydrophobic substances.Therefore, manufacturers can "tune" the dimer to obtain the desired performance profile depending on the formulation and intended use of the treatment composition.

[0020] The compounds, compositions, and related processes of the present disclosure are described in more detail below.

[0021] As used herein, the articles "a" and "an," when used in a claim, are understood to mean one or more of what is claimed or described. As used herein, the terms "include," "includes," and "including" are meant to be open-ended. The compositions of the present disclosure may comprise, consist essentially of, or consist of the components of the present disclosure.

[0022] The terms "substantially free of" or "substantially free from" may be used herein. This means that the indicated material is present in minimal amounts and has not been intentionally added to the composition to form part of the composition, or preferably is not present at analytically detectable levels. It includes compositions in which the indicated material is present only as an impurity in one of the other intentionally included materials. The indicated material, if present at all, may be present at a level of less than 1%, or less than 0.1%, or less than 0.01%, or even 0% by weight of the composition.

[0023] As used herein, the phrase "fabric care composition" includes compositions and formulations designed to treat fabrics. Such compositions include, but are not limited to, laundry cleaning compositions and detergents, fabric softening compositions, fabric enhancing compositions, fabric deodorizing compositions, laundry pre-cleaning agents, laundry pre-treatment agents, laundry additives, spray products, dry cleaning agents or compositions, laundry rinse additives, cleaning additives, post-rinse fabric treatment agents, ironing aids, unit dose formulations, delayed delivery formulations, detergents contained on or in porous substrates or nonwoven sheets, and other suitable forms that may be apparent to those skilled in the art in light of the teachings herein. Such compositions can be used as laundry pre-treatment agents, laundry post-treatment agents, or can be added during the rinse or wash cycle of laundry operations.

[0024] As used herein, the phrase "chain atoms" means the sum of all atoms in the indicated group or moiety, excluding hydrogen atoms. The chain atoms may be in a straight, branched, and / or cyclic arrangement.

[0025] As used herein, "peptide bond" refers to the bond between the C-terminus of one amino acid (or derivative thereof) and the N-terminus of another amino acid (or derivative thereof). As used herein, the phrase "free of peptide bonds" is not intended to exclude the presence of a typical amide bond other than when the amino acids (or derivatives thereof) are in the described C-terminal / N-terminal orientation. Dimers of the present disclosure are typically not intended to include dipeptides, as such materials tend to have reduced loading capacity for benefit agent residues. The reduced loading capacity is generally due to one less nitrogen available for loading of the benefit agent; in dipeptides, the N-terminal nitrogen of one amino acid is typically bonded to the carbonyl carbon of the C-terminus of another amino acid.

[0026] Unless otherwise noted, all ingredient or composition concentrations are in terms of the active portion of that ingredient or composition and are exclusive of impurities, e.g., residual solvents or by-products, that may be present in commercial sources of such ingredient or composition.

[0027] All temperatures herein are in degrees Celsius (°C) unless otherwise indicated. All measurements herein are made at 20°C and atmospheric pressure unless otherwise stated.

[0028] In all embodiments of the present disclosure, all percentages are by weight of the total composition unless otherwise specified. All ratios are by weight unless otherwise specified.

[0029] It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limit given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

[0030] Treatment Composition The present disclosure relates to processing compositions. Processing compositions typically include processing aids and modified amino acid dimer compounds, each of which is discussed in more detail below.

[0031] The treatment composition may be a consumer product composition. The consumer product composition of the present disclosure may be useful in baby care, beauty care, fabric care, home care, family care, feminine care, and / or health care applications. The treatment composition may be useful for treating surfaces such as fabric, hair, or skin. The consumer product composition may be intended to be used or consumed in the manner in which it is sold. The consumer product composition may not be intended for subsequent commercial manufacture or modification.

[0032] The treatment composition may be a fabric care composition. The treatment composition may be a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition (such as a shampoo or conditioner), a body cleansing composition, or a mixture thereof, preferably a fabric care composition.

[0033] The treatment composition may be a fabric care composition such as a laundry detergent composition (including a heavy-duty liquid detergent or unit use article), a fabric conditioning composition (including a liquid fabric softening composition and / or a fabric strengthening composition), a laundry additive, a fabric pretreatment composition (including a spray, pourable liquid, or spray), a fabric refresher composition (including a spray), or a mixture thereof.

[0034] The treatment composition may be a beauty care composition, such as a hair treatment product (including shampoo and / or conditioner), a skin care product (including a cream, lotion, or other topically applied product for consumer use), a shaving care product (including a shaving lotion, foam, or pre- or post-shave treatment), a personal cleansing product (including a liquid body wash, liquid hand soap, and / or bar soap), a deodorant and / or antiperspirant, or mixtures thereof.

[0035] The treatment composition may be a home care composition such as air care, car care, dishwashing, hard surface cleaning and / or treatment, and other consumer or institutional cleaning.

[0036] The treatment composition may be in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a dissolvable sheet, pastilles or beads, a fibrous article, a tablet, a stick, a bar, a flake, a foam / mousse, a nonwoven sheet, or a mixture thereof.

[0037] The treatment composition may be in the form of a liquid. The liquid composition may comprise from about 30%, or from about 40%, or from about 50%, to about 99%, or to about 95%, or to about 90%, or to about 75%, or to about 70%, or to about 60% water by weight of the composition. The liquid composition may be a liquid laundry detergent, a liquid fabric conditioner, a liquid dish detergent, a hair shampoo, a hair conditioner, or a mixture thereof.

[0038] The treatment composition may be in the form of a solid. The solid composition may be a powder or granular composition. Such compositions may be agglomerated or spray-dried. Such compositions may comprise a plurality of granules or particles, at least some of which comprise different compositions. The composition may be a powder or granular cleaning composition, which may include bleach. The composition may be in the form of beads or pastilles, which may be pastilles from a liquid melt. The composition may be an extruded product.

[0039] The treatment composition may be in particulate form, such as a plurality of microparticles. Each microparticle may have a mass of about 1 mg to about 1 g. The emulsion may be dispersed in a water-soluble carrier. The water-soluble carrier may be selected from the group consisting of polyethylene glycol, sodium acetate, sodium bicarbonate, sodium chloride, sodium silicate, polypropylene glycol polyoxoalkylene, polyethylene glycol fatty acid ester, polyethylene glycol ether, sodium sulfate, starch, and mixtures thereof. The water-soluble carrier may be a water-soluble polymer. When in particulate form, the treatment composition may comprise about 25% to about 99.99% by weight of the water-soluble carrier and about 0.001% to about 50% by weight of the dimeric compound of the present disclosure. The particulate form may be in the form of beads or pastilles.

[0040] The treatment composition may be in the form of a unit-dose article such as a tablet, pouch, sheet, or fibrous article. Such pouches typically include a water-soluble film, e.g., a polyvinyl alcohol water-soluble film, that at least partially encapsulates the composition. Suitable films are available from MonoSol, LLC (Indiana, USA). The composition can be enclosed in a single-compartment pouch or a multi-compartment pouch. A multi-compartment pouch may have at least two, at least three, or at least four compartments. A multi-compartment pouch may include compartments arranged side-by-side and / or stacked. The composition contained in the pouch or its compartments may be liquid, solid (e.g., powder), or a combination thereof. The pouch composition may have a relatively low amount of water, e.g., less than about 20%, or less than about 15%, or less than about 12%, or less than about 10%, or less than about 8% by weight of the detergent composition.

[0041] The treatment composition may be in the form of a spray, for example, dispensed via an aerosol container having a trigger sprayer and / or a valve.

[0042] The treatment composition is applied for 20 seconds. -1 and 21°C, 1 to 1500 centipoise (1 to 1500 mPa * s), 100-1000 centipoise (100-1000 mPa * s), or 200 to 500 centipoise (200 to 500 mPa * s).

[0043] Modified Amino Acid Dimer Compounds The present disclosure relates to modified amino acid dimeric compounds. The dimeric compounds contain at least one benefit agent residue, preferably two benefit agent residues. The dimeric compounds can be attached to a target surface, thereby providing the benefit agent residues to the target surface. When the bond holding the residues is cleaved, the benefit agent is released. The release of the benefit agent may be triggered by any suitable mechanism, such as the presence of water or heat, preferably water, especially when the connecting bond is an imine bond. The released benefit agent typically contains an oxygen-containing moiety, i.e., an aldehyde moiety and / or a ketone moiety. As further described herein, the dimeric compounds contain one or more hydrophobic moieties that can promote improved attachment and / or performance efficiency.

[0044] Such dimeric compounds can be part of a treatment composition, as described herein. The treatment composition may comprise from about 0.001% to about 30%, preferably from about 0.001% to about 20%, more preferably from about 0.001% to about 15%, 0.001% to about 10%, and preferably from about 0.01% to about 5% by weight of the modified amino acid dimeric compound. The treatment composition may include the modified amino acid dimeric compound in an amount sufficient to deliver from about 0.01% to about 10%, preferably from about 0.1% to about 5%, by weight of the benefit agent released by the dimeric compound.

[0045] The modified amino acid dimer compounds of the present disclosure comprise two amino acid moieties covalently bonded by a linking group, each amino acid moiety comprising a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom; at least one of the two amino acid moieties comprises one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, the heteroatom being directly bonded to the carbon of the carbonyl group of the amino acid moiety; the linking group is a divalent moiety bonded to a carbon atom of the carbon backbone of each amino acid moiety, the linking group does not comprise a peptide bond, and preferably each of the backbone carbon atoms bonded to the linking group is further bonded directly to a nitrogen atom of a respective amino acid moiety; at least one amino acid moiety comprises an organic moiety covalently bonded to the nitrogen atom of the amino acid moiety, the organic moiety comprising a benefit agent residue that can be cleaved to release a benefit agent, the benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof.

[0046] As described above, the modified amino acid dimeric compound preferably comprises two amino acid moieties covalently linked by a linking group. The dimeric compound comprising each amino acid moiety is typically derived from an amino acid. Proteinogenic amino acids tend to occur naturally, making such compounds attractive for environmental or sustainability reasons and therefore may be preferred starting materials. For most naturally occurring amino acids, the stereogenic carbon alpha to the amino group has the L-configuration. D-amino acids are occasionally found in nature. While either L-amino acids or D-amino acids, as well as mixtures, can be used, economic factors may favor the more abundant L-amino acids. In this context, biosynthetic amino acids may be preferred.

[0047] Each amino acid moiety may comprise a carbon backbone. The carbon backbone may be part of a carbon-containing core, which may also comprise one or more side groups, a nitrogen atom, and a carbonyl group. The carbon backbone is understood to exclude the carbon of the carbonyl-containing moiety or side group (if present). The carbon backbone of each amino acid moiety may independently comprise 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom. For reasons of mass efficiency, a relatively small number of carbon atoms may be preferred. In particular, a backbone comprising only one carbon atom may be preferred, as such a structure is representative of naturally occurring proteinogenic amino acids.

[0048] The carbon-containing core may be derived from an amino acid. Preferably, the core is derived from a proteinogenic amino acid. In particular, naturally occurring or biosynthetic amino acids may be preferred. Such materials may be preferred for environmental / sustainability reasons and because they tend to be readily available at a reasonable cost.

[0049] At least one side group of the parent amino acid derived from the amino acid moiety may be selected from hydrogen or a suitable organic group, preferably hydrogen or an organic group having 1 to about 18 atoms, preferably carbon atoms. The at least one side group may comprise one or more functional groups, such as a carboxyl group, an amine group, a thiol group, or a hydroxyl group. The at least one side group may be linear or branched. The at least one side group may comprise an aryl ring. The amino acid may preferably comprise only one non-hydrogen side group (e.g., only one organic group). The amino acid may comprise two or more non-hydrogen side groups. The at least one side group preferably comprises a side group of a proteinogenic amino acid. The carbon-containing core may comprise at least one side group that is hydrogen and at least one side group that is an organic group. For example, if the amino acid is based on or derived from glycine, all side groups may be hydrogen.

[0050] At least one, and preferably both, amino acid moieties are derived from a proteinogenic amino acid, preferably independently selected from cysteine, glycine, aspartic acid, glutamic acid, lysine, or a combination thereof, more preferably cysteine.

[0051] Amino acids may be chosen for their favorable reactivity profile and / or for the availability of side groups that can be converted into linking groups.

[0052] The two amino acid moieties may be derived from amino acids, preferably proteinogenic amino acids, having the same identity. For example, both amino acid moieties may be derived from cysteine. Both amino acid moieties may be derived from glycine. Forming a dimer from identical amino acids can facilitate convenient and / or predictable reactions (e.g., both amino acid moieties are substantially identical).

[0053] One way in which the dimeric compounds of the present disclosure are "modified" amino acid dimers is that one or both of the amino acid moieties contain a hydrophobic moiety, which may result from a reaction between a hydrophobic substance and the acid moiety of the parent amino acid.

[0054] For example, as noted above, each amino acid moiety contains a carbonyl group, which typically is / was part of the carboxyl group of the parent amino acid. The carbonyl group contains a carbon atom double-bonded to an oxygen atom (C=O).

[0055] At least one of the two amino acid moieties comprises one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, which heteroatom is directly bonded to the carbon of the carbonyl group of the amino acid moiety. If the amino acid moiety does not comprise a hydrophobic moiety bonded to a heteroatom directly bonded to the carbon of the carbonyl group, the carbonyl group may preferably be part of a carboxyl group (—C(O)OH).

[0056] The (parent) amino acid of one or both amino acid moieties can be hydrophobically modified by reacting the carboxylic acid group of the amino acid with (a) an alcohol of an organic group via an esterification reaction, (b) an amine of an organic group via an amidation reaction, or (c) a thiol group of an organic group via a thioesterification reaction. Such reactions can result in ester, amide, or thioester linking groups, respectively. Such linking groups, each of which is a type of carbonyl-containing moiety, may be preferred over others for ease of reaction. Compounds formed using such carbonyl-containing moieties may also be preferred for environmental reasons, as these types of groups can decompose (e.g., hydrolyze) over time and / or in the presence of water, leaving the core material to revert to, for example, a common amino acid.

[0057] The dimeric compounds of the present disclosure include a hydrophobic moiety (sometimes referred to herein simply as a "hydrophobe"). As used in this context, "hydrophobic" refers to an organic group having a logP of at least 1.3, where the logP is determined with respect to the parent alcohol of the organic group, regardless of whether the organic group is derived from an alcohol, amine, or thiol. For example, if the hydrophobe is a linear group having eight carbons and is attached to the heteroatom of the carbonyl-containing moiety at the terminal position of the hydrophobe, the logP is determined according to the logP value of 1-octanol (in this case, logP = approximately 3.0), regardless of whether the hydrophobe is attached to the core via an ester, amide, or thioester bond (see Table A below). The hydrophobic moiety can be characterized by a logP of at least 1.3, or from about 2.8 to about 10.8, or from about 3.0 to about 7.8, or from about 5.0 to about 6.9, where the logP is determined with respect to the parent alcohol of the organic group, the parent alcohol containing an alcohol group (—OH) at the position where the organic moiety is covalently bonded to a heteroatom selected from O, S, or N. Methods for determining logP are found in the Test Methods section below.

[0058] [Table 1] a The logP of individual substances is determined using the Consensus logP Computational Model, version 14.5 (Linux), available from Advanced Chemistry Development Inc. (ACD / Lab), Toronto, Canada.

[0059] As noted above, the hydrophobic moiety can be attached to the carbon-containing core via a carbonyl-containing moiety selected from an ester moiety, an amide moiety, or a thioester moiety. Such a carbonyl-containing moiety can be formed by reacting the carboxylic acid terminus of the core amino acid with an appropriate functional group of a suitable (hydrophobic) organic group (e.g., an alcohol, an amine, or a thiol). The carbonyl-containing moiety attaching the hydrophobic moiety to the core may be preferably an ester moiety, for example, because of the low cost of the alcohol precursor or the favorable environmental profile of the resulting ester.

[0060] As noted above, the hydrophobic moiety may be an organic group containing 5 to 34 chain atoms, preferably carbon atoms. Without being bound by theory, it is believed that a particular minimum number of chain atoms is useful for increasing the relative hydrophobicity of the group and thus the resulting compound, which in turn may help facilitate deposition or increased performance. The hydrophobic moiety may be an organic group containing about 8 to about 18 chain atoms, more preferably about 8 to about 14 chain atoms, and even more preferably, most or even all of the chain atoms are carbon atoms. The chain atoms may preferably be carbon atoms or a mixture of carbon and oxygen atoms forming at least one alkoxylate group.

[0061] It may be preferred that the carbonyl-containing moiety is an amide moiety. An amide moiety may be preferred for stability reasons and / or when the beneficial agent fragment is an antimicrobial fragment. In such cases, the compound may have one or two hydrophobic moieties that are part of the carbonyl-containing moiety. Without being bound by theory, it is believed that two hydrophobic moieties, even if relatively small, can provide a suitable degree of hydrophobicity so that the compound functions similarly to a compound having one larger hydrophobe.

[0062] The one or more hydrophobic moieties of the dimeric compounds described herein may comprise a first hydrophobic moiety and a second hydrophobic moiety. The first and second hydrophobic moieties may be part of the same amino acid moiety, e.g., two hydrophobic moieties on a tertiary nitrogen. The first hydrophobic moiety may be part of the first amino acid moiety, and the second hydrophobic moiety may be part of the second amino acid moiety.

[0063] The one or more hydrophobic moieties may comprise a first hydrophobic moiety and, optionally, a second hydrophobic moiety, wherein at least one of the following is true: (a) at least one of the first hydrophobic moiety and, if present, the second hydrophobic moiety comprises at least 5, preferably at least 8 chain atoms, preferably carbon atoms, and / or (b) when a second hydrophobic moiety is present, the sum of the number of chain atoms, preferably carbon chain atoms, in the first hydrophobic moiety and the second hydrophobic moiety is at least 8, preferably at least 9, more preferably at least 10. Such a minimum number of chain atoms in the hydrophobe(s) may be desirable to provide sufficient hydrophobicity to positively affect deposition efficiency.

[0064] When the benefit agent residue is derived from a perfume raw material, a relatively high degree of hydrophobicity may be preferred for deposition or performance reasons. For example, when the benefit agent to be released is a perfume raw material, the organic group may contain from about 8 to about 18, preferably from about 10 to about 18, more preferably from about 12 to about 18, and even more preferably from about 12 to about 16 chain atoms, preferably with most or even all of the chain atoms being carbon atoms.

[0065] When the benefit agent residue is derived from an antimicrobial agent, a relatively low hydrophobicity may be preferred for performance reasons. For example, when the benefit agent being released is an antimicrobial agent, the organic group may contain from about 5 to about 14, preferably from about 5 to about 12, preferably from about 6 to about 8 chain atoms, preferably the chain atoms are carbon atoms. In such cases, it may be particularly preferred for the hydrophobic moiety to be connected via an amide bond.

[0066] The hydrophobic moiety may be optionally substituted, but such substitutions are preferably selected to maintain the hydrophobicity of the organic group. For example, the organic group may include relatively hydrophobic substitutions. Additionally or alternatively, the organic group may include hydrophilic substitutions, but these are preferably kept to a minimum and / or the number of chain atoms is preferably selected appropriately to offset some of the hydrophilicity of the substitutions. For example, if the organic group includes hydroxyl substitutions, it may be preferred that the organic group include at least 10, preferably at least 12, carbon atoms.

[0067] The hydrophobic moiety may be an unsubstituted organic group, an unbranched organic group, or a combination thereof. Preferably, the hydrophobic moiety is both unsubstituted and unbranched. Such moieties may be preferred due to their convenient availability, performance profile, and relatively low environmental impact. Suitable moieties may be derived from n-octanol, n-decanol, n-dodecanol, etc.

[0068] The hydrophobic moiety may be derived from a mixture of feedstock materials, such as fatty alcohols. The feedstock materials may include materials with varying chain lengths. In such cases, the chain lengths described herein for the hydrophobic moiety are understood to be weight average chain lengths.

[0069] Additionally or alternatively, the feedstock materials used to form the hydrophobic moieties may include some materials that are linear and some materials that are branched. Thus, when the feedstocks are reacted to form the precursors or dimeric compounds of the present disclosure, some materials will include linear monovalent moieties and other materials will include branched monovalent moieties. Such mixtures are contemplated in the present disclosure.

[0070] In addition to one or more beneficial agent residues attached to the nitrogen atom(s) of the amino acid moiety(s), the hydrophobic portion may also contain residues of additional beneficial agents that can eventually be released from the modified amino acid dimer compound. Such a configuration may be preferred for reasons of loading efficiency. Such a configuration may also be preferred to allow various beneficial agents to be released from the same compound.

[0071] For example, the additional benefit agent residue may have a different identity than the benefit agent residue attached to the nitrogen of the core. Both residues may be benefit agents of the same category (e.g., both derived from perfume raw materials), but they may have different identities. Preferably, the first and second benefit agents comprise different functional groups. For example, the first benefit agent may comprise an aldehyde or ketone moiety, and the second benefit agent may comprise a functional group that is not an aldehyde or ketone moiety. The second benefit agent may comprise a functional group that is an alcohol, an amine, a thiol, or a combination thereof.

[0072] Preferably, the second benefit agent contains a functional group that is an alcohol group. Such alcohol-containing materials may be preferred to facilitate reaction with the carboxylic acid of the amino acid core (e.g., thereby forming an ester). Such materials may also be preferred to provide a broader spectrum of materials released from the dimeric compound (e.g., an aldehyde- or ketone-containing benefit agent combined with an alcohol-containing benefit agent).

[0073] The hydrophobic moiety may be substituted with the residue of an additional benefit agent. The hydrophobic moiety may be (in its entirety) the residue of a second benefit agent.

[0074] The additional benefit agent may be a perfume raw material, preferably an alcohol-containing perfume raw material. In such cases, it is preferred that the first benefit agent (e.g., the parent material of the residue attached to the nitrogen atom of the core) is also a perfume raw material, which allows for more efficient perfume delivery and / or a more complex olfactory experience.

[0075] For environmental reasons, it may be preferred that the hydrophobic moiety is derived from a naturally occurring material or feedstock, particularly when the carbon-containing core is derived from a naturally occurring amino acid. Suitable naturally occurring materials or feedstocks may include natural fats and / or oils.

[0076] The hydrophobic moiety may be a monovalent moiety, e.g., a monovalent organic group. For ease of reaction and / or processing reasons, a monovalent hydrophobic moiety may be preferred. In such cases, the hydrophobic moiety is attached to a heteroatom, which is then attached to the carbon of a carbonyl group of a carbon-containing core (e.g., an amino acid derivative), effectively at a terminal or capping position.

[0077] The modified amino acid dimer compounds of the present disclosure comprise two amino acid moieties covalently linked by a linking group. The linking group may be a divalent moiety attached to a carbon atom of the carbon backbone of each amino acid moiety. In particular, in the dimers of the present disclosure, the linking group does not contain a peptide bond. Preferably, each backbone carbon atom attached to the linking group is further directly attached to a nitrogen atom of the respective amino acid moiety.

[0078] The linking group is a divalent organic moiety having 1 to 18 chain atoms, preferably 3 to 18 chain atoms, more preferably 3 to 8 chain atoms, and most preferably 3 to 5 chain atoms. The chain atoms may preferably be selected from carbon atoms, oxygen atoms, sulfur atoms, nitrogen atoms, or combinations thereof.

[0079] The linking group may be derived, at least in part, from at least one side chain of one of the amino acid moieties, preferably from two side chains (one from each amino acid moiety). For example, the two amino acid moieties may be covalently linked by a direct bond, preferably a direct single bond. For example, the two side groups of the parent amino acid of the amino acid moiety may be covalently linked by a direct bond, e.g., a direct single bond. For example, the sulfur atoms of two cysteine ​​side groups may be covalently linked by a direct bond. In such cases, cystine may be the parent amino acid dimer (e.g., the basis of two amino acid moieties) prior to hydrophobic modification.

[0080] The linking group may be derived, for example, by substituting or even replacing one or both side groups of the amino acid moieties. For example, the hydrogen side group of glycine may be substituted at one end of the linking group. Preferably, each end of the divalent linking group replaces the hydrogen side groups of two glycine amino acids or amino acid moieties derived therefrom. Suitable linking groups of this nature may include substituted or unsubstituted alkyl, substituted or unsubstituted aryl, polyalcohol, polyether, alkyl ester, alkylamide, alkylthioester, or mixtures thereof.

[0081] As described above, at least one amino acid moiety includes an organic moiety covalently bonded to a nitrogen atom of the amino acid moiety, the organic moiety including a benefit agent residue. When the bond(s) connecting the residue to the nitrogen atom are cleaved, e.g., upon a triggering event, the dimeric compound releases the benefit agent, which includes an aldehyde moiety, a ketone moiety, or a combination thereof. Such benefit agents are described in more detail below.

[0082] Both amino acid moieties may each include an organic moiety covalently bonded to a nitrogen atom of the respective amino acid moiety. Preferably, both organic moieties attached to their respective nitrogen atoms include benefit agent residues linked by a bond that can be cleaved to release the benefit agent. Such a configuration (e.g., two benefit agent residues on one dimeric compound) may be preferred for reasons of loading efficiency.

[0083] The modified amino acid dimer compounds of the present disclosure may be characterized by a structure according to Formula I:

[0084] [ka]

[0085] In Formula I, L is a linking group containing 1 to 18 chain atoms, the linking group does not contain a peptide bond, and preferably the chain atoms are selected from carbon atoms, oxygen atoms, sulfur atoms, nitrogen atoms, or combinations thereof. For clarity, the linking group may contain an amide bond, so long as it is not a peptide bond. At least one R 3 The group is a hydrophobic moiety, eg, one containing at least 5 carbon atoms.

[0086] In Formula I, each Q is an independently selected carbon-containing core containing 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom. When Q contains 1 carbon atom, the amino acid moiety may be derived from a naturally occurring or biosynthetic proteinogenic amino acid, which may be preferred for environmental reasons.

[0087] In Formula I, each G is —O—, —N(R 6 )-, or -S-, and preferably each G group is the same. 6 When present, R may be selected from —H or a monovalent moiety having a molecular weight of about 15 to about 255 Da, and is preferably 6 is a monovalent moiety having a molecular weight of about 15 to about 142 Da, more preferably a monovalent moiety having a molecular weight of about 15 to about 30 Da. As described below, R 6 and R 3 can act in combination to act as a hydrophobic moiety.

[0088] It may be preferred that G is -O-. The resulting esters when G is -O- may be preferred for environmental reasons as well as for the convenient availability of alcohol-based feedstock materials.

[0089] G is N(R 6 )- is sometimes preferred. 6 Moieties, especially hydrogen, may be preferred for forming amide bonds, for example, due to convenient reaction and availability of feedstock materials. Amides can be formed, for example, from protected or unprotected amino acids. When protected, inorganic and organic acids may be most preferred. For unprotected amino acids, chelate catalysts from Group III elements, Group IV elements, and transition metal catalysts may be preferred. Catalysts containing B, Si, and Ti elements are even more preferred.

[0090] In Formula I, each R 3 are independently selected from H, X, or a monovalent moiety having a molecular weight of about 15 to about 881 Da, preferably a monovalent moiety having a molecular weight of about 43 to about 255 Da, where X is a suitable charge-balancing counterion, provided that at least one R 3 is the monovalent part. The monovalent part R 3 , and, if present, the monovalent moiety R 6 together contain a total of 5 to 34 chain atoms, preferably about 8 to about 18 chain atoms, and more preferably about 8 to about 14 chain atoms. 3 and R 6 is intended to represent the hydrophobic portion of the modified amino acid dimer compound. Preferably, X (if present) is selected from sodium, potassium, lithium, or ammonium.

[0091] In Formula I, each A group is a monovalent nitrogen-containing moiety, and at least one A group comprises a benefit agent residue connected by a bond that can be cleaved to release the benefit agent, the benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof.

[0092] Each A group is independently: (a) H2N-; (b) Z ** N-, (in the formula, ** represents the connecting bond between the nitrogen atom and the carbon atom of the Z group), (c) HG'(J) d N(H)-, and

[0093] [ka] and at least one A group is independently selected from (b) or (d), more preferably at least one A group is selected from the group consisting of (b) Z ** N-, and even more preferably both A groups are selected from (b) Z ** N-, where each Z group is independently selected from a benefit agent residue. The various moieties (e.g., Z, G', J) and subscripts (e.g., d) are described in more detail below.

[0094] At least one A group independently comprises: (b) Z ** N-(in the formula, ** represents the connecting bond between the nitrogen atom and the carbon atom of the Z group, the connecting bond being either (i) a double bond, thereby forming an imine bond, or (ii) the benefit agent from which the benefit agent residue is derived contains an α-β unsaturated carbonyl-containing moiety that is an aldehyde or ketone moiety, and Z ** If the nitrogen atom of the N-group is further bonded to a hydrogen (-H), it may be selected to be one of the single bonds formed from the 1,4-addition).

[0095] In the dimeric compound according to Formula I, at least one A group is (b) Z ** N- is selected from Z ** The Z groups of the N-moiety are independently

[0096] [ka] and mixtures thereof, 4 )(R 5 ) and -CH(R8 )CH2C(O)R 5 Each of the moieties represents a residue of a benefit agent. The residue of the benefit agent preferably has a molecular formula that differs from the molecular formula of the benefit agent only by having one less O atom or one more H atom (e.g., when the benefit agent is derivatized and / or released). The benefit agent includes an aldehyde moiety, a ketone moiety, or a combination thereof, for such moieties to react conveniently with the nitrogen of the amino acid moiety.

[0097] Preferably, the benefit agent is a perfume raw material having 4 to 34 carbon atoms, preferably R 4 are independently selected from monovalent organic moieties; R 5 and R 8 are independently selected from the group consisting of hydrogen and monovalent organic moieties, with the proviso that R 4 and R 5 or R 8 and R 5 may be linked to form a cyclic divalent organic moiety. Preferably, R 5 and R 8 are not both hydrogen in the same Z group. Suitable benefit agents are described in more detail below.

[0098] ** When represents a double bond (e.g., an imine bond), the Z group may be a benefit agent residue having the following structure:

[0099] [ka]

[0100] In such cases, R 4 may be selected from monovalent organic moieties, and R 5 may be selected from the group consisting of hydrogen and monovalent organic moieties, with the proviso that R 4 and R 5 may be linked to form a cyclic divalent moiety. When the Z group is the residue of an aldehyde-containing benefit agent, R 5 is hydrogen. When the Z group is the residue of a ketone-containing benefit agent, R 5is an organic moiety. Such residues have the formula R 4 -C(O)-R 5 The benefit agent and its residue may be characterized by a relatively low molecular weight, for example, from about 100 g / mol to about 1000 g / mol, preferably from about 100 g / mol to about 500 g / mol. 4 and R 5 The groups can be selected accordingly.

[0101] ** When the connecting bond is a single bond, the Z group may be represented by the following structure:

[0102] [ka] During the ceremony, ** represents the point of attachment of the connecting bond to the nitrogen atom (which in this case also includes the hydrogen moiety attached to the nitrogen by a single bond), and R 5 and R 8 is selected from the group consisting of hydrogen and monovalent organic moieties. In such cases, the Z group may be derived from an α-β unsaturated carbonyl (e.g., an aldehyde or ketone). When the Z group is the residue of an aldehyde-containing benefit agent, R 5 is hydrogen. When the Z group is the residue of a ketone-containing benefit agent, R 5 is an organic moiety. Preferably, R 5 and R 8 are not both hydrogens in the same Z group. Such residues have the formula R 8 -CH=CH-C(O)-R 5 The benefit agent may be derived from and / or may result in the release of such a benefit agent.

[0103] At least one A group is independently selected from the group consisting of: (c)HG'(J) d N(H)- or

[0104] [ka] wherein the subscript d is selected from 1 to 3, preferably d is 2 to 3, more preferably d is 2; and each G′ is independently —O—, —S—, or —N(R 7 )-, preferably G' is -O-, the Z group contains 4 to 34 carbon atoms, N and G' are attached to the same carbon atom of the Z group, and each R 7 is, when present, independently selected from —H or a monovalent moiety having a molecular weight of about 15 to about 255 Da, preferably 7 is a monovalent moiety having a molecular weight of about 15 to about 142 Da, more preferably a monovalent moiety having a molecular weight of about 15 to about 30 Da, and each J is independently C(R 9 )2-O- and -N(R 9 ), and preferably each J is selected from the group consisting of C(R 9 )2, and each R 9 are independently selected from H or a monovalent moiety having a molecular weight of 14 to 990 Da, more preferably R 9 is selected from H or a monovalent moiety having a molecular weight between 14 and 186 Da, and even more preferably R 9 is H, provided that the first R 9 and the second R 9 can optionally be combined as a divalent substituent where feasible, and preferably the divalent substituent is selected from fused rings, spirocyclic rings, and ═N(R 7 ), ═O, and ═S; R 7 is as defined above, if present.

[0105] It may be preferred that at least one of the following is true, with the potential benefits of the configurations presented in parentheses: for a given compound, both A groups may contain benefit agent residues (efficient loading); for a given compound, the identities of the A groups are the same (easy processing / dimerization); for a given compound, the identities of the A groups are different (allowing for flexible and / or tunable processing / dimerization); for a given compound, the identities of the Z groups are the same (easy loading and / or efficient delivery of a particular benefit agent); and / or for a given compound, the identities of the Z groups are different (allowing for easy delivery of multiple benefit agents, more complex performance benefits). Two or more of these statements may be true, provided they are not contradictory.

[0106] In the dimeric compound according to formula I, at least one G group is an oxygen atom, and the R bonded to the G group is 3 It may be preferred that the group is a residue of an additional benefit agent (e.g., the additional benefit agent residue acts as the hydrophobic moiety). Preferably, the additional benefit agent is a perfume raw material, and more preferably, the second benefit agent is an alcohol-containing perfume raw material. In such cases, the amino acid moiety is hydrophobically modified by reacting an alcohol-containing perfume raw material with the carboxyl group of the amino acid, thereby forming an ester moiety that is suitably hydrophobic.

[0107] Benefit agents and their residues The modified amino acid dimer compounds of the present disclosure include benefit agent residues derived from aldehyde-containing benefit agents, ketone-containing benefit agents, or a combination thereof. The benefit agent residue may be derived from a benefit agent containing an aldehyde moiety. The benefit agent residue may be derived from a benefit agent containing a ketone moiety. The benefit agent may contain an α-β unsaturated carbonyl group that is an aldehyde or ketone moiety.

[0108] As used herein, the benefit agent from which the benefit agent residue is derived may be referred to as the parent benefit agent.

[0109] The aldehyde or ketone moiety of the parent benefit agent can react with a nitrogen atom of the compound's core (e.g., the nitrogen of an amino acid) to result in a benefit agent fragment attached to the core at the nitrogen atom. As noted above, this can be through a linking bond, which can be a double bond, which is an imine bond, or a single bond formed via a 1,4-addition process, such as a 1,4-Michael-type addition. When the linking bond connecting the benefit agent fragment to the nitrogen atom is formed via 1,4-addition, the parent benefit agent can include an α-β unsaturated carbonyl, where the carbonyl is an aldehyde or ketone moiety.

[0110] When the connecting bonds are broken, for example, by hydrolysis, the benefit agent is released. The connecting bonds can be broken by triggering conditions, such as the presence of water or elevated temperature. When the treatment composition is used to treat fabrics, such triggering conditions can occur during wear, storage, or normal use, such as wiping or toweling a wet surface. The connecting bonds can also be broken under ambient degradation, for example, over time.

[0111] The benefit agent residue may be derived from any suitable benefit agent, which may include a perfume raw material, an antimicrobial, an insecticide, an insect repellent, an antifungal, a herbicide, a hueing dye, an antioxidant, a non-perfume organoleptic, or a combination thereof, preferably a perfume raw material, an antimicrobial, or a combination thereof, more preferably a perfume raw material. Some of these benefit agents are described in more detail below.

[0112] fragrance raw materials The benefit agent may be a perfume raw material ("PRM") that includes an aldehyde moiety, a ketone moiety, or a mixture thereof. The benefit agent residue (e.g., Z group) may be derived from the perfume raw material.

[0113] As used herein, the term "perfume raw material (or "PRM")" refers to a compound that may have a molecular weight of at least about 100 g / mol (optionally up to about 1000 g / mol, preferably up to about 500 g / mol) and that is useful in imparting an odor, fragrance, essence, or scent, either alone or in combination with other perfume raw materials. Lists of common PRMs can be found in various reference sources, such as, for example, "Perfume and Flavor Chemicals," Volumes I and II; Steffen Arctander Allured Pub. Co. (1994) and "Perfumes: Art, Science and Technology," Miller, PM and Lamparsky, D., Blackie Academic and Professional (1994).

[0114] Perfume raw materials containing an aldehyde moiety are provided below in Table B. The materials provided in Table B are believed to be illustrative (but non-limiting) examples of PRMs suitable for use in accordance with the present disclosure.

[0115] [Table 2-1]

[0116] [Table 2-2]

[0117] The perfume raw materials that formed the benefit agent residue may be selected from the group consisting of aldehyde-containing PRMs in Table B above. The PRMs that formed the PRM residue may comprise an aldehyde moiety and are preferably selected from the group consisting of methylnonylacetaldehyde, benzaldehyde, floralozone, isocyclocitral, triplural (ligustral), precyclone B, lilial, decyl aldehyde, undecylenic aldehyde, cyclamen homoaldehyde, cyclamen aldehyde, dupical, oncidal, adoxal, melonal, calypsone, anisaldehyde, heliotropin, cumin aldehyde, scentenal, 3,6-dimethylcyclohexyl methylpropional, ... The cinnamic aldehyde may be selected from the group consisting of hex-3-ene-1-carbaldehyde, satin aldehyde, canthoxal, vanillin, ethyl vanillin, cinnamic aldehyde, cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, Florydral, butyl cinnamaldehyde, limoneral, amyl cinnamaldehyde, hexyl cinnamaldehyde, citronellal, citral, cis-3-hexen-1-al, and mixtures thereof.

[0118] As noted above, the dimeric compound may comprise the residue of a perfume raw material comprising a ketone moiety. Perfume raw materials comprising a ketone moiety are provided below in Table C. The materials presented in Table C are believed to be illustrative (but non-limiting) examples of PRMs suitable for use in accordance with the present disclosure.

[0119] [Table 3-1]

[0120] [Table 3-2]

[0121] The perfume raw materials that formed the benefit agent residue may be selected from the group consisting of aldehyde-containing PRMs in Table C above. The PRM that formed the residue may contain a ketone moiety and may preferably be selected from the group consisting of nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramone, delta-damascone, beta-damascone, alpha-damascone, methyl ionone, 2-hexylcyclopent-2-en-1-one, galbascone, and mixtures thereof.

[0122] The benefit agent residue is a perfume raw material, preferably methylnonyl, acetaldehyde, benzaldehyde, floralozone, isocyclocitral, tripral (ligustral), precyclone B, lilial, decyl aldehyde, undecylenic aldehyde, cyclamen homoaldehyde, cyclamen aldehyde, dupical, oncidal, adoxal, melonal, calypsone, anisaldehyde, heliotropin, cumin aldehyde, scentenal, 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satin aldehyde, canthoxal, vanillin, ethyl vanillin, cinnamic aldehyde, cis-4-decenal, trans- 4-Decenal, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, Florydral, butyl cinnamaldehyde, limoneral, amyl cinnamaldehyde, hexyl cinnamaldehyde, citronellal, citral, cis-3-hexene The PRMs may be derived from a perfume benefit agent that may be selected from the group consisting of methyl-1-al, nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramone, delta-damascone, beta-damascone, alpha-damascone, methyl ionone, 2-hexylcyclopent-2-en-1-one, galbascone, and mixtures thereof. Since mixtures of PRMs are more likely to provide a pleasant odor experience, the materials, preferably those from Tables B and C, may be present as mixtures.

[0123] When the benefit agent residue is derived from a perfume raw material, preferably a PRM listed in the previous paragraph, the hydrophobic moiety may preferably be an organic group containing from about 8 to about 18 chain atoms, more preferably from about 10 to about 18 chain atoms, preferably carbon atoms. Such chain lengths are believed to provide a suitable degree of hydrophobicity to promote deposition benefits, particularly in laundry applications where the dimeric compound is used in aqueous liquors.

[0124] The perfume raw materials herein, including those listed above, are available from a variety of suppliers, including International Flavors and Fragrances of New York, NY USA, Givaudan of Vernier Switzerland, Firmenich of Geneva, Switzerland, Symrise of Holzminden, Germany, Kao of Tokyo, Japan, Takasago of Tokyo, Japan, and Florasynth of Tel-Aviv, Israel.

[0125] B. Antibacterial agents The benefit agent may be an antimicrobial agent comprising an aldehyde moiety, a ketone moiety, or a mixture thereof. Antimicrobial agents suitable for use in the present dimerized compounds may include acetylacetone enolate, gossypol, nootkatone, or a mixture thereof.

[0126] When the beneficial agent residue is derived from an antimicrobial agent, preferably one of those listed in the previous paragraph, the hydrophobic moiety may preferably be an organic group containing from about 5 to about 12 chain atoms, preferably carbon atoms. Such chain lengths are believed to provide a suitable degree of hydrophobicity to promote antimicrobial efficacy and are believed to promote the desired interaction between the antimicrobial agent and the target microorganism.

[0127] Methods for producing modified amino acid dimer compounds and related precursor compounds The modified amino acid dimer compounds according to the present disclosure can be made by reacting a dimer precursor compound with a beneficial agent. Thus, the present disclosure relates to a process for producing the modified amino acid dimer compounds.

[0128] A modified amino acid dimer precursor compound (or "dimer precursor compound" or simply "precursor compound" as used herein) may comprise two covalently linked amino acid moieties. One or both of the amino acid moieties may comprise a hydrophobic moiety.

[0129] For example, a modified amino acid dimer precursor compound of the present disclosure may comprise two amino acid moieties covalently linked by a linking group, each amino acid moiety comprising a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom, at least one of the two amino acid moieties comprising one or more hydrophobic moieties covalently linked to a heteroatom selected from O, S, or N, the heteroatom being directly bonded to the carbon of the carbonyl group of the amino acid moiety, the linking group being a divalent moiety bonded to a carbon atom of the carbon backbone of each amino acid moiety, the linking group being free of peptide bonds, and preferably each of the backbone carbon atoms bonded to the linking group being further directly bonded to a nitrogen atom of the respective amino acid moiety.

[0130] The precursor compound does not (yet) contain a residue of a beneficial agent attached to the nitrogen atom of the amino acid moiety. In fact, the precursor compound may be a modified amino acid dimer compound prior to reaction with the beneficial agent, where the nitrogen atom is in the form of a primary amine (-NH) or HG'(J). d It is in the N(H) form. The core, side groups, carbonyl-containing moiety, and hydrophobic moiety are preferably as described above.

[0131] The modified amino acid dimer precursor compound may have a structure according to Formula I':

[0132] [ka] wherein L, Q, G, and R 3is as defined above, and each A is (a) H2N-, or (b) HG'(J) d N(H)—, and G′, J, and d are as defined above. Other than A, the preferences provided above for the remaining groups or subscripts apply equally to Formula I′.

[0133] The modified amino acid dimer precursor compound may contain two amino acid moieties derived from cysteine. For example, a cystine material may be obtained and hydrophobically modified. Thus, a suitable dimer precursor compound may have a structure according to Formula II:

[0134] [ka] In the formula, G and R 3 is as defined above, except that there is at least one R 3 The group contains at least 5 carbon atoms and each A is independently (a) H2N-, or (b) HG'(J) d N(H)- is a monovalent nitrogen-containing moiety selected from the group consisting of N(H)-, and d is defined as above. Notably, precursor compounds according to Formula II can be formed, in part, by covalently linking the side groups of two cysteine ​​amino acids together to form a -SS bond. Alternatively, a cystine dimer can be provided and then hydrophobically modified.

[0135] The modified amino acid dimer precursor compound may comprise two amino acid moieties derived from substituted glycines. For example, a glycine material may be obtained and hydrophobically modified. Thus, a suitable dimer precursor compound may have a structure according to Formula III:

[0136] [ka] In the formula, G and R 3 is as defined above, except that there is at least one R 3 The group contains at least 5 carbon atoms and each A is independently (a) H2N-, or (b) HG'(J)d N(H)- is a monovalent nitrogen-containing moiety selected from the group consisting of N(H)-, and d is defined as above. Notably, precursor compounds according to Formula II can be formed, in part, by covalently linking the acid side groups of olefin-terminated modified glycine residues together to form a -CC- bond. Alternatively, modified glycine dimers can be provided and then hydrophobically modified.

[0137] The modified amino acid dimer precursor compound may comprise two amino acid moieties derived from glutamic acid. For example, a glutamic acid material may be obtained and hydrophobically modified. Thus, a suitable dimer precursor compound may have a structure according to Formula IV:

[0138] [ka] In the formula, G and R 3 is as defined above, except that there is at least one R 3 The group contains at least 5 carbon atoms and each A is independently (a) H2N-, or (b) HG'(J) d N(H)- is a monovalent nitrogen-containing moiety selected from the group consisting of: N(H)-, and G', J, and d are as defined above. Notably, precursor compounds according to Formula IV can be formed, in part, by covalently linking the side groups of two glutamic acid amino acids together to form an ester bond. Alternatively, a glutamic acid dimer can be provided and then hydrophobically modified.

[0139] The modified amino acid dimer precursor compound may comprise two distinct amino acid moieties derived from glutamic acid and lysine. For example, a modified lysine material may be obtained and hydrophobically modified. Thus, a suitable dimer precursor compound may have a structure according to Formula V:

[0140] [ka] In the formula, G and R 3 is as defined above, except that there is at least one R 3The group contains at least 5 carbon atoms and each A is independently (a) H2N-, or (b) HG'(J) d N(H)- is a monovalent nitrogen-containing moiety selected from the group consisting of N(H)-, and d is defined as above. Notably, precursor compounds according to Formula V can be formed, in part, by covalently linking the side groups of lysine and glutamic acid amino acids together to form an amide bond. Alternatively, modified lysine dimers can be provided and then hydrophobically modified.

[0141] Dimeric amino acid materials can be prepared by converting the carboxyl groups of the amino acids into the following formula: HGR 3 The compound may be hydrophobically modified by reacting it with a compound according to the formula (I) above, for example by esterification, amidation, or thioesterification reactions.

[0142] Accordingly, the present disclosure provides a method of producing a modified amino acid dimer precursor compound, the method comprising: providing an amino acid dimer, optionally by dimerizing two amino acids such that the two amino acids are covalently linked by a linking group to form the amino acid dimer; and reacting the amino acid dimer with at least one hydrophobic moiety to form an ester, amide, or thioester, wherein the hydrophobic moiety comprises at least 5 carbon atoms, preferably 5 to 18 carbon atoms, and more preferably 8 to 18 carbon atoms.

[0143] The hydrophobically modified amino acid dimer precursor compound can be prepared by (i) providing one molar equivalent of an amino acid moiety containing a carboxylic acid terminus, and (ii) adding an approximately equal equivalent of a hydrophobic material (e.g., a compound of formula HGR) to form a mixture. 3(iii) combining the mixture of amino acid moieties and hydrophobic material with a slight molar excess of acid (preferably sulfuric acid, methanesulfonic acid, or para-toluenesulfonic acid, or a mixture thereof) in a suitable reaction vessel; (iv) heating the combined mixture at 100° C. to 150° C. for 1 hour to 36 hours; (v) adjusting the pH to at least about 7; and (vi) separating at least a portion of the salt formed during neutralization from the product.

[0144] The dimeric precursor compounds (and / or dimeric precursor compositions produced by the methods provided herein) may be reacted with a beneficial agent to form the modified amino acid dimeric compounds described herein.

[0145] Supplementary ingredients The treatment compositions of the present disclosure, which may be consumer products, may include auxiliary materials that may provide a benefit in the intended end use of the composition or may be processing and / or stabilizing aids.

[0146] Suitable adjunct materials may include surfactants, conditioning actives, deposition aids, rheology modifiers or structurants, antioxidants, bleaching systems, stabilizers, builders, chelating agents, dye transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clay and soil removal / anti-redeposition agents, brighteners, suds suppressors, silicones, hueing agents, aesthetic dyes, neat fragrance, fragrance delivery systems (such as core / shell capsules and other pro-fragrance materials), structural elastomers, carriers, hydrotropes, processing aids, anti-agglomerating agents, coatings, formaldehyde scavengers, and / or pigments.

[0147] Depending on the intended form, formulation, and / or end use, the compositions of the present disclosure may or may not contain one or more of the following adjunct materials: surfactants, conditioning actives, deposition aids, rheology modifiers or structurants, antioxidants, bleach activators, surfactants, builders, chelating agents, dye transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clays and soil removal / anti-redeposition agents, brighteners, suds suppressors, dyes, additional perfumes and perfume delivery systems, structural elastomers, fabric softeners, carriers, hydrotropes, processing aids, structurants, anti-agglomerating agents, coatings, formaldehyde scavengers, and / or pigments.

[0148] The exact nature of these additional components and the concentration at which they are incorporated depend on the physical form of the composition and the nature of the work to be used. However, if one or more adjuvants are present, such one or more adjuvants can be present as detailed below. The following is a non-limiting list of suitable additional adjuvants:

[0149] A. Surfactants The treatment composition of the present disclosure may include a surfactant. The surfactant may be useful, for example, to provide cleaning benefits. The composition may include a surfactant system, which may contain one or more surfactants.

[0150] Treatment compositions of the present disclosure may comprise from about 0.1% to about 70%, or from about 2% to about 60%, or from about 5% to about 50% by weight of the composition of a surfactant system. Liquid compositions may comprise from about 5% to about 40% by weight of the composition of a surfactant system. Compositions suitable for dense formulations, e.g., dense, liquid, gel, and / or unit dose forms, may comprise from about 25% to about 70%, or from about 30% to about 50% by weight of the composition of a surfactant system.

[0151] The surfactant system may include anionic surfactants, nonionic surfactants, zwitterionic surfactants, cationic surfactants, amphoteric surfactants, or combinations thereof. The surfactant system may include nonionic surfactants such as linear alkyl benzene sulfonates, alkyl ethoxylated sulfates, alkyl sulfates, ethoxylated alcohols, amine oxides, or mixtures thereof. The surfactant may be derived, at least in part, from natural sources, such as natural feedstock alcohols.

[0152] Suitable anionic surfactants may include any conventional anionic surfactant. This may include, for example, sulfate detersive surfactants for alkoxylated and / or non-alkoxylated alkyl sulfate materials, and / or sulfonic acid-based detersive surfactants, such as alkyl benzene sulfonates. The anionic surfactant may be linear, branched, or a combination thereof. Preferred surfactants include linear alkyl benzene sulfonates (LAS), alkyl ethoxylated sulfates (AES), alkyl sulfates (AS), or mixtures thereof. Other suitable anionic surfactants include branched-chain modified alkyl benzene sulfonates (MLAS), methyl ester sulfonates (MES), sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), and / or alkyl ethoxylated carboxylates (AEC). The anionic surfactant may be present in acid form, salt form, or a mixture thereof. The anionic surfactants may be partially or totally neutralized, for example, with an alkali metal (eg, sodium) or an amine (eg, monoethanolamine).

[0153] The surfactant system may include a nonionic surfactant. Suitable nonionic surfactants include alkoxylated fatty alcohols, such as ethoxylated fatty alcohols. Other suitable nonionic surfactants include alkoxylated alkylphenols, alkylphenol condensates, mid-chain branched alcohols, mid-chain branched alkyl alkoxylates, alkyl polysaccharides (e.g., alkyl polyglycosides), polyhydroxy fatty acid amides, ether-capped poly(oxyalkylated) alcohol surfactants, and mixtures thereof. The alkoxylate units may be ethyleneoxy units, propyleneoxy units, or mixtures thereof. The nonionic surfactant may be linear, branched (e.g., mid-chain branched), or a combination thereof. Specific nonionic surfactants may include alcohols having an average of about 12 to about 16 carbons and an average of about 3 to about 9 ethoxy groups, such as C12-C14 EO7 nonionic surfactants.

[0154] Suitable zwitterionic surfactants include betaines, C8-C9 alkyl dimethyl betaines, including alkyl dimethyl betaines and cocodimethylamidopropyl betaine. 18 (For example, C 12 ~C 18 ) amine oxides (e.g., C 12 ~ 14 dimethylamine oxide), and / or N-alkyl-N,N-dimethylamino-1-propanesulfonate (wherein the alkyl group is C8 to C 18 or C 10 ~C 14 The zwitterionic surfactant may include any conventional zwitterionic surfactant, such as sulfo and hydroxybetaines, such as (which may be

[0155] Depending on the formulation and / or intended end use, the composition may be substantially free of certain surfactants. For example, a liquid fabric strengthening composition, such as a fabric softener, may be substantially free of anionic surfactants, as such surfactants may negatively interact with cationic components.

[0156] B. Conditioning Actives The treatment compositions of the present disclosure may also include conditioning actives. Compositions containing conditioning actives may provide softness, anti-wrinkle, anti-static, conditioning, anti-stretch, color, and / or appearance benefits.

[0157] The conditioning active may be present at a level of about 1% to about 99% by weight of the composition. The composition may comprise from about 1%, or about 2%, or about 3%, to about 99%, or about 75%, or about 50%, or about 40%, or about 35%, or about 30%, or about 25%, or about 20%, or about 15%, or about 10% conditioning active by weight of the composition. The composition may comprise from about 5% to about 30% conditioning active by weight of the composition.

[0158] Suitable conditioning actives for the compositions of the present disclosure may include quaternary ammonium ester compounds, silicones, non-ester quaternary ammonium compounds, amines, fatty acid esters, sucrose esters, silicones, dispersible polyolefins, polysaccharides, fatty acids, softening or conditioning oils, polymer latexes, polyhydroxystearic acid and / or its derivatives, glyceride copolymers, or combinations thereof. Preferably, the conditioning active is a cationic conditioning active, which may improve delivery / deposition of the dimeric compound.

[0159] The treatment composition may include a conditioning active, the conditioning active comprising a quaternary ammonium ester compound. Preferably, the quaternary ammonium ester compound is present at a concentration of about 2% to about 35% by weight of the treatment composition, preferably about 4% to about 25% by weight, more preferably about 5% to about 20% by weight, even more preferably about 6% to about 15% by weight, and even more preferably about 7% to about 12% by weight. The quaternary ammonium ester compound (also known as an "ester quaternary ammonium") may be a monoester quaternary ammonium, a diester quaternary ammonium, a triester quaternary ammonium, or a combination thereof. Preferably, the diester quaternary ammonium material forms a major portion (whether majority or plural) of the ester quaternary ammonium compound. In addition to providing conditioning benefits, it is believed that selecting the appropriate type and / or concentration of the conditioning active (i.e., the quaternary ammonium ester compound) can improve deposition and / or performance of the dimeric compounds described herein.

[0160] The quaternary ammonium ester compound may include a compound according to the formula: {R 2 (4-m) -N+-[XYR 1 ] m}A - m is 1, 2, or 3, provided that in a given molecule, each value of m is the same; Each R may contain 13 to 22 carbon atoms. 1 are independently a linear or branched hydrocarbyl group, preferably R 1 is linear, and more preferably, R 1 is a partially unsaturated linear alkyl chain, Each R 2 are independently a C1-C3 alkyl group or a hydroxyalkyl group, and / or each R 2is selected from methyl, ethyl, propyl, hydroxyethyl, 2-hydroxypropyl, 1-methyl-2-hydroxyethyl, poly(C2-C3 alkoxy), polyethoxy, benzyl, more preferably methyl or hydroxyethyl; each X is independently -(CH2)n-, -CH2-CH(CH3)-, or -CH(CH3)-CH2-, where each n is independently 1, 2, 3, or 4, preferably, each n is 2; each Y is independently —O—(O)C— or —C(O)—O—; A- is independently selected from the group consisting of chloride, bromide, methyl sulfate, ethyl sulfate, sulfuric acid, and nitric acid; preferably, A- is selected from the group consisting of chloride and methyl sulfate; more preferably, A- is methyl sulfate.

[0161] For monoester quaternary ammonium, m is 1. For diester quaternary ammonium, m is 2. For triester quaternary ammonium, m is 3. The conditioning active may comprise a mixture of monoester and diester quaternary ammonium, or even a mixture of monoester, diester, and triester quaternary ammonium. As will be appreciated by those skilled in the art, the mixture may depend, in part, on the starting / feedstock materials, such as dialkanolamine or trialkanolamine.

[0162] The quaternary ammonium ester compound can be derived from a fatty acid characterized by an iodine value of 0 to 140, or 0 to about 90, or about 10 to about 70, or about 15 to about 50, or about 18 to about 30. The iodine value can be determined according to the method provided in U.S. Patent Application Publication No. 2020 / 0407665 (equivalent to WO 2020 / 264566).

[0163] The composition may contain a quaternary ammonium ester compound, a silicone, or a combination of these, preferably a single combination. The total amount of the quaternary ammonium ester compound and the silicone may be about 5% to about 70% by weight, or about 6% to about 50% by weight, or about 7% to about 40% by weight, or about 10% to about 30% by weight, or about 15% to about 25% by weight of the composition. The composition may contain the quaternary ammonium ester compound and the silicone in a weight ratio of about 1:10 to about 10:1, or about 1:5 to about 5:1, or about 1:3 to about 1:3, or about 1:2 to about 2:1, or about 1:1.5 to about 1.5:1, or about 1:1.

[0164] The composition may contain a mixture of different types of conditioning actives. The composition of the present disclosure may contain a specific conditioning active but may be substantially free of other conditioning actives. For example, the composition may be free of quaternary ammonium ester compounds, silicones, or both. The composition may contain a quaternary ammonium ester compound but may be substantially free of silicones. The composition may contain silicones but may be substantially free of quaternary ammonium ester compounds.

[0165] The conditioning active may include a glyceride copolymer. The glyceride copolymer may be derived from a natural oil. Examples of natural oils include, but are not limited to, vegetable oils, algae oils, fish oils, animal fats, tall oil, derivatives of these oils, and combinations of these oils. Representative, non-limiting examples of vegetable oils include low-erucic-acid rapeseed oil (canola oil), high-erucic-acid rapeseed oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, linseed oil, palm kernel oil, tung oil, jatropha oil, mustard oil, pennycress oil, camelina oil, hempseed oil, and castor oil, preferably canola oil. Representative, non-limiting examples of animal fats include lard, tallow, poultry oil, yellow grease, and fish oil. Tall oil is a by-product of wood pulp production. The glyceride copolymer may be a metallated unsaturated polyol ester.

[0166] C. Adhesion aid The treatment composition of the present disclosure may also include a deposition aid. The deposition aid can promote deposition of various benefit agents, including the dimeric compounds of the present disclosure, conditioning actives, fragrances or fragrance delivery systems (such as encapsulated fragrances), or combinations thereof, improving the performance benefits of the composition and / or allowing for more efficient formulation of such benefit agents. The composition may comprise 0.0001% to 3%, preferably 0.0005% to 2%, more preferably 0.001% to 1%, or about 0.01% to about 0.5%, or about 0.05% to about 0.3% of the deposition aid by weight of the composition. The deposition aid may be a cationic or amphoteric polymer, preferably a cationic polymer.

[0167] Cationic polymers in general and methods for their preparation are well known in the literature. Suitable cationic polymers include quaternary ammonium polymers known as "polyquaternium" polymers, as designated in the International System of Nomenclature for Cosmetic Ingredients, such as Polyquaternium-6 (poly(diallyldimethylammonium chloride)), Polyquaternium-7 (copolymer of acrylamide and diallyldimethylammonium chloride), Polyquaternium-10 (quaternized hydroxyethylcellulose), and Polyquaternium-22 (copolymer of acrylic acid and diallyldimethylammonium chloride).

[0168] The deposition aid may be selected from the group consisting of polyvinyl formamide, partially hydroxylated polyvinyl formamide, polyvinyl amine, polyethylene imine, ethoxylated polyethylene imine, polyvinyl alcohol, polyacrylate, and combinations thereof.

[0169] The cationic polymer may comprise a cationic acrylate and / or a cationic methacrylate. Such polymers may be copolymers further comprising a nonionic monomer, such as acrylamide. The cationic polymer may be linear or crosslinked. The deposition aid may comprise a combination of a linear cationic polymer and a crosslinked cationic polymer.

[0170] The deposition aid can be added simultaneously with the delivery particles (e.g., simultaneously with an encapsulated benefit agent such as an encapsulated perfume) or directly / independently into the consumer product composition. The weight average molecular weight of the polymer may be 500 to 5,000,000 daltons, or 1,000 to 2,000,000 daltons, or 2,500 to 1,500,000 daltons, as measured by size exclusion chromatography against polyethylene oxide standards using refractive index (RI) detection. The weight average molecular weight of the cationic polymer may be 5,000 to 37,500 daltons.

[0171] D. Fragrances and / or Fragrance Delivery Systems Perfume The treatment compositions of the present disclosure may include a perfume and / or perfume delivery system. This may be true even if the benefit agent residue of the dimeric compound is derived from a perfume raw material.

[0172] The treatment compositions of the present disclosure may also contain other perfume raw materials, including PRMs that do not contain aldehyde or ketone moieties, for example, in undiluted or free form. For example, the other PRMs may be provided as undiluted or free oils in the premix compositions and / or treatment compositions of the present disclosure, even if they do not react with the dimeric precursor compounds. Such mixtures may be desirable, for example, to provide a more appropriate olfactory experience.

[0173] The treatment composition of the present disclosure may further comprise undiluted perfume, preferably undiluted perfume raw materials that do not contain aldehyde or ketone moieties. Preferably, the undiluted perfume comprises an alcohol-containing perfume raw material. Suitable alcohol-containing perfume raw materials are known to those skilled in the art and may include geraniol, citronellol, cinnamic alcohol, eugenol, etc. However, the undiluted perfume may further comprise free perfume raw materials that contain aldehyde and / or ketone moieties.

[0174] The treatment composition of the present disclosure may additionally or alternatively include a perfume delivery system. Such a perfume delivery system may take the form of a polymer-assisted delivery system. Such a perfume delivery system may take the form of an encapsulation, for example a core-shell encapsulation, in which the core contains the perfume raw material and is surrounded by a polymer shell. The polymer shell may comprise a polymer material derived from polyacrylate, polyurea, polyurethane, polysaccharide, polyvinyl alcohol, melamine, derivatives thereof, or combinations thereof. Additionally or alternatively, a suitable perfume delivery system may include known pro-perfume / pro-fragrance materials.

[0175] Other ingredients The treatment compositions and / or premix compositions of the present disclosure may contain unreacted reactants and / or decomposition products of the dimeric compounds described herein. For example, the treatment compositions and / or premix compositions of the present disclosure may contain parent amino acids, dimerized amino acids, hydrophobically modified single amino acids, hydrophobically modified dimerized amino acids (e.g., modified amino acid precursor compounds described above), free forms of hydrophobic substances (e.g., HGRs, such as fatty alcohols, e.g., dodecanol), and the like. 3 The carbon-containing core may also include precursors or derivatives of the carbon-containing core alone, such as amino acid dimer compounds in hydrophobic-free form, free benefit agents (e.g., aldehyde- or ketone-containing PRMs), or combinations thereof. Dimerized amino acids (hydrophobically modified or otherwise) may react with other materials found in the formulation, for example, when the benefit agent residue is replaced with the residue of a different material found in the formulation, particularly when such material contains an aldehyde or ketone moiety. It is recognized that such reactions may occur in situ, although not intentionally.

[0176] Premix The present disclosure further relates to certain premix compositions and methods of making such compositions. The premixes can be conveniently prepared prior to product formulation, and can even be prepared at one manufacturing site and shipped to another manufacturing site for product formulation.

[0177] The premix composition may include a dimeric precursor compound (wherein the precursor compound is as described above) and a benefit agent (wherein the benefit agent is as described above). The preferences discussed above with respect to the dimeric compound, its components, and / or its precursors apply here as well. The premix composition may optionally include water. The premix composition may further include, preferably, a non-aqueous solvent, more preferably a hydroxyl-containing solvent, and even more preferably ethanol.

[0178] For example, a premix composition may include a modified amino acid dimer precursor compound, wherein the precursor compound comprises a carbon-containing core, the core comprising side groups and amine groups, and a hydrophobic moiety attached to the core by a carbonyl moiety, the carbonyl moiety being selected from an ester moiety, an amide moiety, or a thioester moiety; a benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof; and optionally water.

[0179] For reasons of loading efficiency, it is preferable to reasonably match the molar amount of the benefit agent, preferably the first benefit agent, to the molar amount of the amino acid moiety in the modified amino acid dimer precursor compound. Typically, a dimer precursor has two molar equivalents of amino acid moiety, so this is two moles of benefit agent per mole of dimer precursor. For example, the premix composition may contain the modified amino acid dimer precursor compound and the benefit agent in a molar ratio of about 1:1 to about 1:3, preferably about 1:1.5 to about 1:2.5, more preferably about 1:2.

[0180] Even more specifically, for reasons of loading efficiency, it is preferred that the molar amount of the benefit agent, preferably the first benefit agent, be reasonably matched to the molar equivalent of the reactive functional groups (e.g., preferably amine groups) of the carrier molecule (here, the modified amino acid dimer precursor compound) described above. For example, the premix composition may comprise the modified amino acid dimer precursor compound and the reactive functional groups (e.g., preferably amine groups) of the benefit agent in a molar ratio of about 3:1 to about 1:3, preferably about 2:1 to about 1:2, preferably about 1.5:1 to about 1:1.5, more preferably about 1.2:1 to about 1:1.2, and even more preferably about 1:1. When the modified amino acid dimer precursor compound contains multiple points of attachment, or multiple functional groups capable of forming such points of attachment, to the benefit agent and, optionally, to the second benefit agent, the premix composition may contain such functional groups of the modified amino acid dimer precursor compound and the benefit agent (plus, optionally, additional benefit agents which may also be attached to the precursor compound, for example, as a hydrophobic material) present in a molar ratio of from about 3:1 to about 1:3, preferably from about 2:1 to about 1:2, preferably from about 1.5:1 to about 1:1.5, more preferably from about 1.2:1 to about 1:1.2, and even more preferably about 1:1.

[0181] The premix composition may be in the form of a neat fluid, with little or no water present. In such cases, it may be desirable to include a water scavenger, such as magnesium sulfate, in the premix and / or physically remove the water, such as through molecular sieves or in a vacuum. The premix composition may contain less than about 10% by weight of water, preferably less than about 5% by weight, more preferably less than about 1% by weight, and even more preferably less than about 0.1% by weight of the premix composition. Low-moisture premix compositions may be particularly preferred when intended to be formulated into low-moisture product compositions, such as solids like pastilles, or compact formulations, such as unit-dose compositions encapsulated in a water-soluble film. When the premix is ​​a low-moisture premix, the premix may comprise from about 1% to about 100% by weight of the premix composition, preferably from about 5% to about 100% by weight, and more preferably from about 20% to about 100% by weight of the modified amino acid dimer precursor compound. When the premix is ​​a low moisture premix, the premix may comprise from about 0.01% to about 80%, preferably from about 0.01% to about 20%, by weight of the premix composition of the modified amino acid dimer precursor compound.When the premix is ​​a low moisture premix, the premix may comprise from about 0.01% to about 80%, preferably from about 0.01% to about 20%, by weight of the premix composition of the benefit agent.

[0182] The premix composition may comprise a non-aqueous solvent, more preferably a hydroxyl-containing solvent, even more preferably ethanol, in an amount of up to 50% by weight of the premix composition, preferably from about 5% to about 50%, more preferably from about 10% to about 25%, and even more preferably from about 10% to about 15%.

[0183] The premix composition may contain water. The premix composition may be in the form of an emulsion, preferably an oil-in-water emulsion. When the premix is ​​in the form of an emulsion and contains water, the water may be present at a concentration of about 50% to about 95% by weight of the premix composition, preferably about 60% to about 90% by weight. When the premix contains water, the modified amino acid dimer precursor compound may be added at a concentration of about 0.01% to about 7.5% by weight of the premix composition. When the premix contains water, the benefit agent may be added at a concentration of about 0.01% to about 7.5% by weight of the premix composition.

[0184] In the premix composition, the modified amino acid dimer precursor compound and the benefit agent may react as described above to form the modified amino acid dimer compound. The precursor compound, benefit agent, and modified amino acid dimer compound may all exist in equilibrium. Because the formation of certain modified amino acid dimer compounds, such as those containing imines, produces water through a condensation process, the equilibrium may be biased toward the reactant side of the reaction (e.g., the precursor compound and the benefit agent) if the premix contains water. Conversely, if the premix is ​​substantially free of intentionally added water, a relatively large amount of modified amino acid dimer compound may be present, but it is recognized that some water will be formed as a result of the condensation reaction. When the formation of the modified amino acid dimer compound involves 1,4-addition, the equilibrium is not dependent on water, but rather on the balance between entropic and enthalpic contributions.

[0185] The total weight percentage of the modified amino acid dimer precursor, benefit agent, and, if present, the modified amino acid dimer compound may be from about 10% to about 100% by weight of the premix composition, preferably from about 25% to about 100% by weight, preferably from about 50% to about 100% by weight, and more preferably from about 75% to about 100% by weight.

[0186] A premix composition or portion thereof can be obtained by combining from about 1 part by weight to about 99 parts by weight, preferably from about 5 parts by weight to about 80 parts by weight, of a modified amino acid dimer precursor compound with from about 1 part by weight to about 99 parts by weight, preferably from about 5 parts by weight to about 80 parts by weight of a benefit agent, the resulting mixture being understood to comprise a total of 100 parts by weight.

[0187] The premix composition may include multiple precursors, multiple benefit agents, and / or multiple modified amino acid dimer compounds. The premix composition may further include additional agents that do not react to form modified amino acid dimer compounds according to the present disclosure. For example, the premix composition may include additional PRMs, surfactants, solvents, or other processing or stabilizing aids.

[0188] The premix composition may also include a surfactant, preferably a nonionic surfactant, which may aid in the stability of the premix composition and / or the emulsification process.

[0189] The present disclosure further relates to methods for making such premix compositions. The method may include combining a modified amino acid dimer precursor described herein with a benefit agent described herein, wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof. The materials may be combined in the ratios provided above. The method may include removing or otherwise binding free water, which may help promote the reaction in the premix toward the product (e.g., a dimeric compound). If the premix composition includes water, the precursor compound and water may preferably be combined before the benefit agent is added. Alternatively, the benefit agent and water may be mixed before the benefit agent is added.

[0190] Method for producing the treatment composition The present disclosure relates to a process for producing any of the compositions described herein. The process for producing a treatment composition, which may be a consumer product, preferably a fabric care composition, may include combining the modified amino acid dimer compound described herein with the auxiliary material described herein.

[0191] The modified amino acid dimer compound may be combined with such auxiliary materials by methods including mixing and / or spraying.

[0192] The compositions of the present disclosure can be formulated into any suitable form and prepared by any process selected by the formulator. The modified amino acid dimer compound and auxiliary materials may be combined in a batch process, a circulation loop process, and / or an in-line mixing process. Suitable equipment for use in the methods disclosed herein may include continuous stirred tank reactors, homogenizers, turbine agitators, recirculation pumps, paddle mixers, high shear mixers, static mixers, plow shear mixers, ribbon blenders, vertical shaft granulators and drum mixers (both batch and, where available, in continuous process configurations), spray dryers, and extruders.

[0193] For example, a method for preparing a treatment composition may include combining a modified amino acid dimer compound according to the present disclosure with a base composition, preferably a liquid base composition, including auxiliary ingredients. This process can be carried out, for example, by a batch process or an in-line mixing process, preferably an in-line mixing process.

[0194] The method for producing a treatment composition may include combining a modified amino acid dimer precursor compound, a benefit agent, and an auxiliary component, as described herein. Preferably, the auxiliary component is part of the base composition, and the dimer precursor compound and the benefit agent are each added to the base composition as separate inputs. The separate inputs may be added sequentially (e.g., consecutively) or substantially simultaneously. Preferably, the base composition is a liquid. This process may be carried out, for example, by a batch process or an in-line mixing process, preferably an in-line mixing process.

[0195] The method for producing a treatment composition may include adding a premix to a base composition. The premix composition may include a modified amino acid dimer precursor compound and a benefit agent, as described herein. The premix composition may be obtained by combining a modified amino acid dimer precursor compound and a benefit agent, as described herein. The premix composition may include a modified amino acid dimer compound according to the present disclosure, for example, due to the reaction of a precursor compound with a benefit agent. The premix composition may include a mixture of a modified amino acid dimer precursor compound, a benefit agent, and a modified amino acid dimer compound. The premix may optionally contain water. This process may be carried out, for example, by a batch process or an in-line mixing process, preferably an in-line mixing process. The premix may be particularly preferred when producing a treatment composition that is or will be in a solid form, such as a PEG-based pastille. In such cases, removal or reduction of water from the premix may be useful, for example, via a water scavenger such as magnesium sulfate, or via the use of molecular sieves or evaporation under vacuum.

[0196] How to treat the surface The present disclosure further relates to methods of treating surfaces (e.g., surfaces of articles) with treatment compositions according to the present disclosure, which may provide cleaning, conditioning, hygiene, and / or cooling benefits.

[0197] Suitable surfaces may include fabrics (including clothing, towels, or linens), hard surfaces (such as tile, porcelain, linoleum, or wood floors), dishware, hair, skin, or mixtures thereof.

[0198] The method may include contacting an article or surface with a treatment composition of the present disclosure, optionally in the presence of water, and may further include optionally rinsing and / or drying the article or surface. The treatment composition may be in neat form or may be diluted with a liquid, such as a cleaning or rinsing liquid. The treatment composition may be diluted with water before, during, or after contact with the surface or article. The surface or article may optionally be washed and / or rinsed before and / or after the contacting step.

[0199] The method for treating and / or cleaning a surface may comprise the following steps. a) optionally cleaning, rinsing, and / or drying the surface; b) contacting the surface with a treatment composition described herein, optionally in the presence of water; c) optionally cleaning and / or rinsing the surface; and d) Optionally drying by passive drying and / or by active methods such as a washer dryer.

[0200] For purposes of the present invention, cleaning includes, but is not limited to, scrubbing and mechanical agitation. Fabrics may include most any fabric that can be laundered or treated under normal consumer or industrial use conditions.

[0201] Liquids that can contain the disclosed compositions can have a pH of about 3 to about 11.5. When diluted, such compositions are typically used at concentrations of about 500 ppm to about 15,000 ppm in solution. When the cleaning solvent is water, the water temperature typically ranges from about 5°C to about 90°C, and when the surface is a piece of fabric, the weight ratio of water to fabric is typically about 1:1 to about 30:1.

[0202] The present disclosure further discloses a process for treating a surface or article, preferably a fabric, with an aqueous treatment solution comprising a modified amino acid dimer compound according to the present disclosure, wherein preferably the benefit agent residue is a residue of a perfume raw material or an antimicrobial agent, preferably a fragment of a perfume raw material. The method may include contacting the surface or article, preferably the fabric, with the aqueous solution. The dimer compound may be present in the aqueous solution at a concentration of from about 0.001 ppm by weight (e.g., 1 ppb) to about 1000 ppm by weight.

[0203] The present disclosure further discloses a process for treating a surface or article, preferably a fabric, with an aqueous treatment solution comprising a modified amino acid dimer precursor compound according to the present disclosure and a benefit agent according to the present disclosure. The benefit agent may be a perfume raw material or an antimicrobial agent, preferably a perfume raw material. The method may include contacting the surface or article, preferably a fabric, with the aqueous solution. The dimer precursor compound may be present in the aqueous solution at a concentration of about 0.001 ppm by weight (e.g., 1 ppb) to about 1000 ppm by weight.

[0204] use The present disclosure relates to the use of modified amino acid dimers as described herein to provide freshness benefits when the modified amino acid dimers comprise residues of perfume raw materials, particularly when part of a treatment composition.

[0205] The present disclosure relates to the use of modified amino acid dimer compounds described herein to provide antimicrobial effects, particularly when the modified amino acid dimer compounds comprise fragments of antimicrobial agents, when they are part of a treatment composition.

[0206] The present disclosure relates to the use of modified amino acid dimer compounds as described herein to provide anti-malodor benefits, particularly when part of a treatment composition.

[0207] combination Specifically contemplated combinations of the present disclosure are set forth herein in the following alphabetized sections, which are exemplary in nature and not intended to be limiting.

[0208] A. A treatment composition comprising: a treatment aid; and a modified amino acid dimer compound, the dimer compound comprising two amino acid moieties covalently bonded by a linking group, each amino acid moiety comprising a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom, at least one of the two amino acid moieties comprising one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, the heteroatom being bonded directly to the carbon of the carbonyl group of the amino acid moiety, the linking group being a divalent moiety bonded to a carbon atom of the carbon backbone of each amino acid moiety, the linking group being free of peptide bonds, and preferably each of the backbone carbon atoms bonded to the linking group being further bonded directly to a nitrogen atom of a respective amino acid moiety, at least one amino acid moiety comprising an organic moiety covalently bonded to the nitrogen atom of the amino acid moiety, the organic moiety comprising a benefit agent residue that can be cleaved to release a benefit agent, the benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof.

[0209] B. The treating composition of paragraph A, wherein the carbon backbone of each amino acid moiety independently contains 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom.

[0210] C. The treatment composition of either paragraph A or B, wherein the linking group is a divalent organic moiety having 1 to 18 chain atoms, preferably 3 to 18 chain atoms, more preferably 3 to 8 chain atoms, and most preferably 3 to 5 chain atoms.

[0211] D. The treatment composition of any of paragraphs A-C, wherein the two amino acid moieties are covalently linked by a direct single bond.

[0212] E. The treating composition of any of paragraphs A-D, wherein the linking group is derived, at least in part, from at least one side chain of one of the amino acid moieties, preferably from two side chains from each amino acid moiety.

[0213] F. The treatment composition of any of paragraphs A-E, wherein at least one, and even more preferably both, amino acid moieties are derived from a proteinogenic amino acid, preferably a proteinogenic amino acid independently selected from cysteine, glycine, aspartic acid, glutamic acid, lysine, or combinations thereof, more preferably cysteine.

[0214] G. The treating composition of any of paragraphs A-F, wherein the two amino acid moieties are derived from amino acids having the same identity, preferably derived from proteinogenic amino acids having the same identity.

[0215] H. The treatment composition of any of paragraphs A-G, wherein both amino acid moieties each comprise an organic moiety covalently bonded to a nitrogen atom of the respective amino acid moiety, and preferably both organic moieties bonded to the nitrogen atom comprise a benefit agent residue that can be cleaved to release the benefit agent.

[0216] I. The treating composition of any of paragraphs A-H, wherein the one or more hydrophobic moieties is an organic group having a logP of at least 1.3, preferably from about 2.8 to about 10.8, more preferably from about 3.0 to about 7.8, and even more preferably from about 5.0 to about 6.9, where the logP is determined with respect to a parent alcohol of the organic group, the parent alcohol comprising an alcohol group (—OH) at the position where the organic moiety is covalently bonded to a heteroatom selected from O, S, or N.

[0217] J. The treatment composition of any of paragraphs A-I, wherein the one or more hydrophobic moieties comprise a first hydrophobic moiety and, optionally, a second hydrophobic moiety, and wherein at least one of the following is true: (a) at least one of the first hydrophobic moiety and, if present, the second hydrophobic moiety comprises at least 5, preferably at least 8 chain atoms, preferably carbon atoms; and / or (b) a second hydrophobic moiety is present, and the sum of the number of chain atoms, preferably carbon chain atoms, in the first hydrophobic moiety and the second hydrophobic moiety is at least 8, preferably at least 9, more preferably at least 10.

[0218] K. The treatment composition of any of paragraphs A-J, wherein the one or more hydrophobic moieties are unsubstituted hydrocarbons, unbranched hydrocarbons, or combinations thereof.

[0219] L. A treatment composition comprising a treatment aid and a modified amino acid dimer compound, the modified amino acid dimer compound having Formula I:

[0220] [ka] wherein L is a linking group comprising 1 to 18 chain atoms, the linking group does not comprise a peptide bond, and preferably the chain atoms are selected from carbon atoms, oxygen atoms, nitrogen atoms, sulfur atoms, or combinations thereof; each Q is independently selected from a carbon-containing core comprising 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom; each G is independently selected from -O-, -N(R 6 )-, or -S-, preferably each G group is the same; R 6 is, if present, selected from —H or a monovalent moiety having a molecular weight of about 15 to about 255 Da, preferably R 6 is a monovalent moiety having a molecular weight of about 15 to about 142 Da, more preferably about 15 to about 30 Da, and each R 3 are independently selected from H, X, or a monovalent moiety having a molecular weight of about 15 to about 881 Da, preferably a monovalent moiety having a molecular weight of about 43 to about 255 Da, and X is a suitable charge-balancing counterion, provided that at least one R 3 is a monovalent part, and R 3 and, if present, R 6 and the monovalent moieties of the formula (A) together comprise a total of 5 to 34 chain atoms, preferably about 8 to about 18 chain atoms, and more preferably about 8 to about 14 chain atoms, each A group being a monovalent nitrogen-containing moiety, and at least one A group comprising a benefit agent residue that can be cleaved to release a benefit agent, wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof.

[0221] M. Each A group is independently: (a) H2N-, (b) Z ** N-, wherein ** represents the connecting bond between the nitrogen atom and the carbon atom of the Z group, the connecting bond being either (i) a double bond, thereby forming an imine bond, or (ii) the benefit agent from which the benefit agent residue is derived contains an α-β unsaturated carbonyl-containing moiety that is an aldehyde or ketone moiety, and Z ** If the nitrogen atom of the N-group is further bonded to a hydrogen (-H), it is one of the single bonds formed from the 1,4-addition), (c) HG'(J) d N(H)-, and

[0222] [ka] wherein the subscript d is selected from 1 to 3, preferably d is 2 to 3, more preferably d is 2; and each G′ is independently —O—, —S—, or —N(R 7 )-, preferably G' is -O-, the Z group contains 4 to 34 carbon atoms, N and G' are attached to the same carbon atom of the Z group, and each R 7 is, when present, independently selected from —H or a monovalent moiety having a molecular weight of about 15 to about 255 Da, preferably 7 is a monovalent moiety having a molecular weight of about 15 to about 142 Da, more preferably a monovalent moiety having a molecular weight of about 15 to about 30 Da, and each J is independently C(R 9 )2 and -N(R 9 ), and preferably each J is selected from the group consisting of C(R 9 )2, and each R 9 are independently selected from H or a monovalent moiety having a molecular weight of 14 to 990 Da, more preferably R 9 is selected from H or a monovalent moiety having a molecular weight between 14 and 186 Da, and even more preferably R 9 is H, provided that the first R 9 and the second R 9can optionally be combined as a divalent substituent where feasible, and preferably the divalent substituent is selected from fused rings, spirocyclic rings, and ═N(R 7 ), ═O, and ═S; R 7 is as defined above), and at least one A group is independently selected from (b) or (d), more preferably at least one A group is selected from the group consisting of (b) Z ** N-, and even more preferably both A groups are selected from (b) Z ** The treatment composition of paragraph L, wherein each Z group is selected from N- and each Z group is an independently selected benefit agent residue.

[0223] N. At least one A group is (b) Z ** N- is selected from Z ** The Z groups of the N-moiety are independently

[0224] [ka] and mixtures thereof, 4 (R 5 ) and -CH(R 8 )CH2C(O)R 5 each of the moieties represents a residue of a benefit agent, the residue of the benefit agent having a molecular formula that differs from the molecular formula of the benefit agent only by having one less O atom or one more H atom, the benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof, preferably the benefit agent is a perfume raw material containing from 4 to 34 carbon atoms, preferably R 4 are independently selected from monovalent organic moieties, R 5 and R 8 are independently selected from the group consisting of hydrogen and monovalent organic moieties, with the proviso that R 4 and R 5 or R 8 and R 5 may be linked to form a cyclic divalent organic moiety.

[0225] The treatment composition of any of paragraphs LN, wherein OX is a suitable charge-balancing counterion selected from sodium, potassium, lithium, or ammonium.

[0226] P. The treatment composition of any of paragraphs L-O, wherein at least one of the following is true: both A groups comprise a benefit agent residue; for a given compound, the identities of the A groups are the same; for a given compound, the identities of the A groups are different; for a given compound, the identities of the Z groups are the same; and / or for a given compound, the identities of the Z groups are different.

[0227] The QZ group has the following structure:

[0228] [ka] The treatment composition of any of paragraphs L-P, wherein the benefit agent residue has the formula:

[0229] R. In compounds according to formula I, at least one G group is an oxygen atom and R bonded to the G group 3 is a residue of a second benefit agent, preferably the second benefit agent is a perfume raw material, more preferably the second benefit agent is an alcohol-containing perfume raw material.

[0230] S. The treatment composition of any of paragraphs A-R, wherein the benefit agent residue is a residue of a benefit agent selected from a fragrance raw material, an antimicrobial, an insecticide, an insect repellent, an antifungal, a herbicide, a hueing dye, an antioxidant, a non-fragrance organoleptic, or a combination thereof, preferably a fragrance raw material, an antimicrobial, or a combination thereof.

[0231] T. Benefit agents include fragrance raw materials, preferably methylnonylacetaldehyde, benzaldehyde, floralozone, isocyclocitral, triplal (ligustral), precyclone B, lilial, decyl aldehyde, undecylenic aldehyde, cyclamen homoaldehyde, cyclamen aldehyde, dupical, oncidal, adoxal (adoxal), melonal, calypsone, anisaldehyde, heliotropin, cuminaldehyde, scentenal, 3,6-dimethylcyclohex-3-ene-1-carbaldehyde, satinaldehyde, canthoxal, vanillin, ethyl vanillin, cinnamic aldehyde, cis-4-decenal, trans-4-decena ol, cis-7-decenal, undecylenic aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, Florydral, butylcinnamaldehyde, limoneral, amylcinnamaldehyde, hexylcinnamaldehyde, citronellal, citral, cis-3-hexen-1-al, The treating composition of any of paragraphs A through S, wherein the perfume raw material may be selected from the group consisting of nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalen-2-ylethanone, nectaryl, trimofix O, fluramone, delta-damascone, beta-damascone, alpha-damascone, methyl ionone, 2-hexylcyclopent-2-en-1-one, galbascone, and mixtures thereof.

[0232] U. The treatment composition of any of paragraphs A-T, wherein the adjunct ingredients include one or more of surfactants, conditioning actives, deposition aids, rheology modifiers or structurants, acid inhibitors, bleaching systems, stabilizers, builders, chelating agents, dye transfer inhibitors, dispersants, enzymes, enzyme stabilizers, catalytic metal complexes, polymeric dispersants, mud and soil removal / anti-redeposition agents, brighteners, suds suppressors, silicones, hueing agents, aesthetic dyes, neat fragrances, fragrance delivery systems, structural elastomers, carriers, hydrotropes, processing aids, anti-agglomerating agents, coatings, formaldehyde scavengers, and / or pigments.

[0233] V. The treatment composition of any of paragraphs A-U, wherein the adjunct ingredients include a conditioning active, preferably the conditioning active includes a quaternary ammonium ester compound, more preferably the quaternary ammonium ester compound is present at a concentration of from about 2% to about 35%, preferably from about 4% to about 25%, more preferably from about 5% to about 20%, preferably from about 6% to about 15%, more preferably from about 7% to about 12% by weight of the treatment composition.

[0234] W. The treatment composition of any of paragraphs A-V, wherein the treatment composition further comprises a neat perfume, preferably a neat perfume comprising an alcohol-containing perfume raw material, an ester-containing perfume raw material, or a combination thereof.

[0235] X. The treatment composition of any of paragraphs A-W, wherein the treatment composition is a consumer product, preferably a consumer product selected from a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition, a body cleansing composition, or mixtures thereof.

[0236] Y. The treatment composition of any of paragraphs A-X, wherein the treatment composition is in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a dissolvable sheet, a pastille or bead, a fibrous article, a tablet, a stick, a bar, a flake, a foam / mousse, a nonwoven sheet, or a mixture thereof.

[0237] Z. The treatment composition of any of paragraphs A through Y, wherein the dimeric compound is present in the treatment composition at a concentration of from about 0.001% to about 30% by weight of the treatment composition.

[0238] AA. A modified amino acid dimer compound according to any of paragraphs A-Z.

[0239] BB. Modified amino acid dimer precursor compounds according to Formula I',

[0240] [ka] (Wherein L, Q, G, and R 3 is as defined above, and each A is (a) H2N-, or (b) HG'(J) d N(H)-, wherein G', J, and d are monovalent nitrogen-containing moieties independently selected from the group consisting of: N(H)-, G', J, and d are as defined above.

[0241] CC. A premix composition comprising a modified amino acid dimer precursor compound described in paragraph BB, a benefit agent, and optionally water, wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof, and preferably further comprising a non-aqueous solvent, more preferably a hydroxyl-containing solvent, even more preferably ethanol.

[0242] DD. A method of making a treatment composition described in any of paragraphs A-Z, comprising at least one of: (a) combining a modified amino acid dimer compound with an adjunct component, preferably wherein the adjunct component is part of the base composition; (b) combining a premix composition described in paragraph CC with an adjunct component, preferably wherein the adjunct component is part of the base composition; and (c) combining a modified amino acid dimer precursor compound, a benefit agent, and an adjunct component, preferably wherein the adjunct component is part of the base composition and wherein the modified amino acid dimer compound and the benefit agent are each added as separate inputs to the base composition.

[0243] EE. A method of treating an article or surface, comprising treating the article or surface with a treatment composition described in any of paragraphs A-Z, optionally in the presence of water, and optionally further comprising rinsing and / or drying the article or surface.

[0244] Test Method It will be understood that the test methods disclosed in the Test Methods section of this application should be used to determine the values ​​of each of the parameters of the inventive subject matter claimed and described herein.

[0245] HLB value of nonionic surfactants Nonionic surfactants can be classified by the balance between the hydrophilic and lipophilic moieties in the surfactant molecule. The hydrophilic-lipophilic balance (HLB) scale, devised by Griffin in 1949, is a scale of 0 to 20 (20 being hydrophilic) used to characterize the properties of surfactants. The HLB of a surfactant can be calculated as follows: HLB=20 * Mh / M (where Mh is the molecular weight of the hydrophilic portion of the molecule, M is the molecular weight of the entire molecule, and the result is given on a scale of 0 to 20.) An HLB value of 0 corresponds to a completely lipophilic / hydrophobic molecule, while a value of 20 corresponds to a completely hydrophilic / lipophobic molecule. See Griffin, W.C., Calculation of HLB values ​​of Nonionic Surfactants, J. Soc. Cosmet. Chem. 1954, 5, 249-256. HLB values ​​of commonly used surfactants are readily available in the literature (e.g., HLB index in McCutcheon's Emulsifiers and Detergents, MC Publishing Co., 2004). The HLB value of a surfactant mixture can be calculated as a weighted average of the HLB values ​​of the surfactants.

[0246] Test Method for Determining logP Logarithm of the octanol / water partition coefficient (logP) values ​​are calculated for materials as described herein (such as alcohol versions of hydrophobes / Q groups or PRMs).

[0247] The logP of individual substances was calculated using the Consensus logP Computational Model, version 14.5 (Linux), available from Advanced Chemistry Development Inc. (ACD / Lab) (Toronto, Canada), which provides unitless logP values. The ACD / Labs Consensus logP Computational Model is part of the ACD / Labs model suite.

[0248] Preparation of Test Fabric Enhancer / Softener Compositions A 7.5% by weight N,N-di(tallowoyloxyethyl)-N,N-dimethylammonium chloride in water mixture is provided. The premix fluid described above, the premix emulsion described above, or two separate undiluted fluids (one a dimer precursor such as a modified amino acid, and the other a benefit agent such as one or more perfume raw materials) are added in amounts such that the concentration of benefit agent or benefit fragment in the fabric softener is approximately 0.3% by weight of the final fabric softener composition. The mixture is stirred for 5 minutes at 350 rpm using an IKA RW 20 D S1 mixer, model RW20DS1, and an IKA R1342 impeller blade. A structurant and deposition aid are added, and the mixture is stirred for 10 minutes. Water is added, if necessary, to standardize the concentration of N,N-di(tallowoyloxyethyl)-N,N-dimethylammonium chloride between the test legs to 7.3% by weight, and the mixture is stirred for 5 minutes. If necessary, the pH is adjusted to 2-3 with HCl.

[0249] Fabric Preparation Method To prepare fabrics for headspace analysis testing, fabric samples (100% cotton terrycloth, item number ITL 1022-15PGP, Calderon Textiles, Inc. 6131 W. 80tA St., Indianapolis, IN 46278, desized and conditioned with three wash cycles of detergent and fabric softener) are treated with detergent or fabric softener in a manner consistent with North American consumers through a clothes mini-washer, a full-scale washer, and a clothes dryer. Prior to headspace GCMS analysis (see methods below), fabrics are equilibrated at 21.1°C and 50% relative humidity for 12-24 hours, unless otherwise noted. Ballast loads consist of cotton and polycotton knit swatches approximately 20 x 20 inches (50 x 50 cm) in size.

[0250] Cleaning treatment conditions In the following fabric enhancer / softener composition performance test, fabrics are treated under the following wash process conditions: Wash: 12 minutes agitation, 30.6°C. Rinse: 2 minutes agitation, 15.5°C. Water hardness: 137 ppm. Water: 7.6 pH. Fabric load weight: 290 g. Tumble dry setting: 50 minutes high, cotton. Detergent dosage: 9.65 g. Fabric softener dosage: 5.71 g.

[0251] The detergent used was unscented liquid TIDE Original Scent (manufactured by The Procter & Gamble Company).

[0252] Headspace analysis on fabric The following procedure is used to determine the level of benefit agent material in the headspace on the fabric.

[0253] The following equipment is used: Gas Chromatograph 7890B equipped with a Mass Selective Detector (5977B) (MSD) and ChemStation Quantitative Package, Gerstel Multipurpose Sampler equipped with a solid-phase microextraction (SPME) probe or similar system, divinylbenzene / Carboxen / polydimethylsiloxane SPME fiber from Supleco part #57298-U (or similar fiber), nominal diameter 30 m x 0.25 mm, film thickness 0.25 m, J&W 122-5532UI DB-5, 20 mL headspace vial.

[0254] To prepare the fabric for analysis, cut three 2.54 cm x 5.08 cm cotton swatches from the cotton terry prepared and treated as described above. Place each piece into a 20 mL headspace vial and cap.

[0255] The Gerstel autosampler parameters were as follows: SPME from the incubator, incubation temperature - 65 °C, incubation time - 10.00 min. Sample parameters: vial penetration volume - 22.00 mm, extraction time - 5.00 min, initial penetration volume - 54.00 mm, desorption time - 300 s. The GC oven parameters for the front SS inlet He were as follows: mode - splitless, heater: 270 °C, GC run time - 14.28 min. For the oven, initial temperature - 40 °C, hold time - 0.5 min, heating program - rate of 17 °C / min, temperature of 270 °C, hold time - 0.25 min. The MSD parameters were as follows: scan mode, run with a minimum m / z range of 35 to 350.

[0256] Generate a calibration curve from standard benefit agent materials. Calculate the headspace mass using the calibration curve for each perfume ingredient in the ChemStation software (or similar quantitation software). [Example]

[0257] The examples provided below are intended to be illustrative and not limiting in nature.

[0258] Synthesis Examples The following Synthesis Examples 1, 2A, and 2B illustrate the synthesis of exemplary modified amino acid dimer compounds (eg, Synthesis Example 1) and their modified amino acid dimer precursors (eg, Synthesis Example 1′) according to the present disclosure.

[0259] For consistency and illustrative / comparative purposes, each example reacts a different undiluted precursor molecule with the same perfume raw material, cyclamen aldehyde (containing an aldehyde moiety). As an additional example (formed via 1,4 addition), Synthesis Example 2B forms a modified amino acid dimer compound with a delta-damascone containing a ketone moiety. The structure of the PRM is shown below:

[0260] [ka]

[0261] However, it is understood that other aldehyde- or ketone-containing benefit agents according to the present disclosure may also result in the formation of suitable modified amino acid dimer compounds, some of which are exemplified and tested in the performance examples below.

[0262] It is also understood that the synthetic examples may be formulated into the treatment composition as a liquid premix emulsion, or as a neat fluid, or as a low-water liquid premix fluid as described above. However, for the performance and stability examples reported below, all synthetic examples are assumed to be formulated directly into the treatment composition as a liquid premix fluid, optionally using a solvent such as ethanol, unless otherwise indicated.

[0263] For each synthesis example, the resulting modified amino acid dimer compound (e.g., modified amino acid ester molecule), designated as a cyclamen aldehyde (see Synthesis Examples 1 and 2A), or delta-damascone in the case of Synthesis Example 2B, is provided in Table D below.

[0264] Method for preparing modified amino acid dimer compounds In the following synthetic examples, materials are generally obtained / available from Sigma-Aldrich (St. Louis, MO, USA) except where indicated below. Amino acids are generally provided at >98% or even >99% purity. Alcohols are generally provided at >97%, >98%, or even >99% purity. Cyclamen aldehyde (e.g., Sigma-Aldrich) is provided at >95% purity. δ-Damascone is available from Firmenich (Geneva, Switzerland).

[0265] General Method A: General Preparation of Modified Amino Acid Dimer Precursor Compounds To prepare the modified amino acid dimer precursor compounds exemplified herein from amino acids and alkyl alcohols, a round-bottom flask is charged with 1 molar equivalent of the free base dimerized amino acid starting material (which may be supplied in dimerized form or formed from individual amino acids by known dimerization techniques). 2.2 equivalents of alcohol are added to the flask, followed by 2.2 equivalents of p-toluenesulfonic acid monohydrate (PTSA) or methanesulfonic acid (MsOH). The flask is then diluted with toluene and refluxed for 12 hours using a Dean-Stark apparatus. The solvent is removed in vacuo, and the resulting crude material is dissolved in chloroform. The solution is neutralized with Et3N, then washed three times with NaHCO3 and dried over MgSO4. The solvent is removed, and the washed material is diluted with cyclohexane and stored at 0°C for 12 hours. The eluate is collected to give the desired modified amino acid ester.

[0266] General Method B: General Preparation of Modified Amino Acid Dimer Compounds A round-bottom flask is charged with one equivalent of the modified amino acid ester precursor. Either cyclamen aldehyde or δ-damascene is added to the flask in an equimolar amount relative to the primary amine of the modified amino acid dimer precursor. For heterogeneous mixtures, 10-15 wt% solvent is added, as exemplified in the synthesis example below. 20 wt% 4 Å molecular sieves are added to the fluid, and the mixture is stirred for 12 hours. The resulting mixture is filtered using a Pyrex 36060-30M Brand 36060 fritted funnel and used directly.

[0267] Synthesis Example 1 Synthesis Example 1' was prepared as described in General Method A, except that 10 g of L-leucine, 17.0 g of dodecanol, and 17.4 g of PTSA H2O were used. The isolated fluid of Synthesis Example 1' was then mixed with cyclamen aldehyde as described in General Method B to obtain Synthesis Example 1. Independent Fluid 1 was 1 It appears stable for several months by 1 H NMR.

[0268] Synthetic Example 2A Synthesis Example 2' was prepared as described in General Method A, except that 5.0 g of 2,6-diaminoheptanedioic acid, 10.5 g of dodecanol, and 11 g of PTSA HO were used. The isolated fluid of Synthesis Example 2' was then mixed with 15 wt % ethanol and cyclamen aldehyde as described in General Method B to obtain Synthesis Example 2A. The isolated fluid 2A was 1 It appears stable for several months by 1 H NMR.

[0269] Synthetic Example 2B Synthesis Example 2' was prepared as described in General Method A, except that 5.0 g of 2,6-diaminoheptanedioic acid, 10.8 g of dodecanol, and 11.1 g of PTSA HO were used. The isolated fluid of Synthesis Example 2' was then mixed with 15 wt % ethanol and δ-damascene as described in General Method B to obtain Synthesis Example 2B. The isolated fluid 2B was 1It appears stable for several months by 1 H NMR.

[0270] Structures of synthetic examples. Table D below shows the structures of Synthetic Examples 1, 2A, and 2B, as well as their precursor compounds (indicated by "'").

[0271] [Table 4]

[0272] In the following performance examples, modified amino acid dimer precursor compounds (e.g., amino acid ester dimer compounds) and the indicated perfume raw materials are mixed substantially according to procedures consistent with those found in the synthesis examples above. Despite the differences in preparation methods (e.g., made with different pro-benefit agents) between the synthesis examples and the performance and stability examples, the inputs and outputs for the modified amino acid dimer compounds are substantially the same.

[0273] Performance example In the following Performance Example 1, treatment compositions containing undiluted perfume oil or modified amino acid dimer compounds (e.g., based on modified amino acid esters) according to the present disclosure are compared through treatment cycles in an automatic washing machine according to the fabric treatment method described above. After treatment, the fabrics are tested for headspace analysis according to the test method provided above. The following data demonstrate the benefits provided by hydrophobically modified amino acid (ester) dimer compounds and their interaction with benefit agents via imines or 1,4-adducts in the delivery of the benefit agents.

[0274] Performance Example 1. Application in liquid fabric enhancers with a series of modified amino acid esters In the following examples, the aldehyde benefit agent listed in each test leg is provided with a modified amino acid dimer precursor as described above, and then formulated into a test fabric enhancer / softener composition prepared as provided in the test method above. The test fabrics are prepared, wash treated, and tested for headspace analysis on the fabric according to the test method above.

[0275] For rows in Table 1 labeled "Synthetic Example 1," etc., it is understood that a sample was prepared substantially according to the methods and precursors provided in the recited Synthetic Example, but using not only cyclamen aldehyde or delta-damascone but also the benefit agent material listed in the Performance Table (at equimolar concentrations to the amine content in the modified amino acid dimer precursor) and formulated as a premix fluid as detailed above.

[0276] The results of the above headspace analysis fabric tests are shown in Table 1 below.

[0277] [Table 5] a The formulation was 0.3% by weight and consisted of: 10% by weight methylnonylacetaldehyde, 40% by weight PT Bucinal, 20% by weight Precyclemon B, and 30% by weight Floralozone.

[0278] As shown in Table 1, modified amino acid dimer compounds 1 and 2 provided improved total headspace compared to the pure raw materials.

[0279] Additionally, the heteroatom-containing linking group (including S-S bonds) in Synthesis Example 1 provides an improvement in overall delivery of the benefit agent. Minor variations in delivery efficiency of individual benefit agents are observed between Synthesis Examples 1 and 2. For example, headspace in Synthesis Example 2 is superior for PT Bucinal (relatively less sterically hindered) compared to Aldehyde Floral Ozone (relatively more sterically hindered).

[0280] Dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise indicated, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm."

[0281] All documents cited herein, including any cross-referenced or related patents or patent applications, and any patent applications or patents to which this application claims priority or benefit, are incorporated herein by reference in their entirety, unless expressly stated to the contrary. The citation of any document shall not be deemed to be prior art to any invention disclosed or claimed herein, or to teach, suggest, or disclose any such invention, either alone or in combination with any other reference or references. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.

[0282] While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention. [1] 1. A treatment composition comprising: a processing aid; a modified amino acid dimer compound; the dimeric compound comprises two amino acid moieties covalently linked by a linking group; each amino acid moiety comprises a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom; at least one of the two amino acid moieties comprises one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, the heteroatom being directly bonded to the carbon of the carbonyl group of the amino acid moiety; the linking group is a divalent moiety attached to a carbon atom of the carbon backbone of each amino acid moiety; the linking group does not contain a peptide bond, Preferably, each of the backbone carbon atoms bonded to the linking group is also directly bonded to the nitrogen atom of a respective one of the amino acid moieties; at least one amino acid moiety comprises an organic moiety covalently bonded to the nitrogen atom of the amino acid moiety; the organic moiety comprises a benefit agent residue that can be cleaved to release the benefit agent; A treatment composition wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof. [2] The treatment composition according to [1], wherein the carbon backbone of each amino acid moiety independently contains 1 to 9 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and even more preferably 1 carbon atom. [3] The treatment composition according to [1] or [2], wherein the linking group is a divalent organic moiety having 1 to 18 chain atoms, preferably 3 to 18 chain atoms, more preferably 3 to 8 chain atoms, and most preferably 3 to 5 chain atoms. [4] The treatment composition according to [1] or [2], wherein the two amino acid moieties are covalently linked by a direct single bond. [5] The treatment composition according to any one of [1] to [4], wherein the linking group is derived, at least in part, from at least one side chain of one of the amino acid moieties, preferably from two side chains from each amino acid moiety. [6] At least one, and even more preferably both, of said amino acid moieties is a proteinogenic amino acid, Preferably, proteinogenic amino acids independently selected from cysteine, glycine, aspartic acid, glutamic acid, lysine, or combinations thereof; More preferably, the treatment composition according to any one of [1] to [5] is derived from cysteine. [7] the two amino acid moieties are derived from amino acids having the same identity; Preferably, the treating composition according to any one of [1] to [6] is derived from a proteinogenic amino acid having the same identity. [8] each of said amino acid moieties comprises an organic moiety covalently bonded to the nitrogen atom of said respective amino acid moiety; Preferably, both of the organic moieties attached to the nitrogen atom comprise a benefit agent residue that can be cleaved to release a benefit agent.

[0023] The treatment composition according to any one of [1] to [7]. [9] the one or more hydrophobic moieties are organic groups having a log P of at least 1.3, preferably from about 2.8 to about 10.8, more preferably from about 3.0 to about 7.8, and even more preferably from about 5.0 to about 6.9; the logP is determined for the parent alcohol of the organic group; The treatment composition according to any one of [1] to [8], wherein the parent alcohol contains an alcohol group (—OH) at a position where the organic moiety is covalently bonded to a heteroatom selected from O, S, or N.

[10] the one or more hydrophobic moieties include a first hydrophobic moiety and optionally a second hydrophobic moiety; below: (a) at least one of the first hydrophobic moiety and, if present, the second hydrophobic moiety, comprises at least 5, preferably at least 8, chain atoms, preferably carbon atoms; and / or (b) the second hydrophobic moiety is present and the sum of the number of chain atoms, preferably carbon chain atoms, in the first hydrophobic moiety and the second hydrophobic moiety is at least 8, preferably at least 9, more preferably at least 10; The treatment composition according to any one of [1] to [9], wherein at least one of the following is true:

[11] The treatment composition according to any one of [1] to

[10] , wherein the one or more hydrophobic moieties are unsubstituted hydrocarbons, unbranched hydrocarbons, or a combination thereof.

[12] 1. A treatment composition comprising: a processing aid; and a modified amino acid dimer compound, the modified amino acid dimer compound having Formula I:

change

[13] Each A group is independently (a)H 2 N-、 (b)Z ** N-、 (In the formula, ** represents the connecting bond between the nitrogen atom and the carbon atom of the Z group, said connecting bond being (i) a double bond, thereby forming an imine bond, or (ii) the benefit agent from which the benefit agent residue is derived comprises an α-β unsaturated carbonyl-containing moiety that is an aldehyde moiety or a ketone moiety; and ** If the nitrogen atom of the N-group is further bonded to a hydrogen (-H), it is one of the single bonds formed from the 1,4-addition; (c)HG'(J) d N(H)-, and (d)

change

[12] The treatment composition of

[12] , wherein each Z group is an independently selected benefit agent residue.

[14] At least one A group is (b) Z ** N-, wherein Z ** The Z groups of the N-moiety are independently

change

[12] or

[13] , selected from the group consisting of: and mixtures thereof.

[15] The treatment composition according to any one of

[12] to

[14] , wherein X is a suitable charge-balancing counterion selected from sodium, potassium, lithium, or ammonium.

Claims

1. 1. A treatment composition comprising: a processing aid; a modified amino acid dimer compound; the dimeric compound comprises two amino acid moieties covalently linked by a linking group; each amino acid moiety comprises a carbon backbone comprising one or more carbon atoms, a carbonyl group comprising a carbon atom, and a nitrogen atom; at least one of the two amino acid moieties comprises one or more hydrophobic moieties covalently bonded to a heteroatom selected from O, S, or N, the heteroatom being directly bonded to the carbon of the carbonyl group of the amino acid moiety, and the one or more hydrophobic moieties are organic groups having a log P of at least 1.3; the linking group is a divalent moiety attached to a carbon atom of the carbon backbone of each amino acid moiety; the linking group does not contain a peptide bond, at least one amino acid moiety comprises an organic moiety covalently bonded to the nitrogen atom of the amino acid moiety; the organic moiety comprises a benefit agent residue that can be cleaved to release the benefit agent; A treatment composition wherein the benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof.

2. 10. The treating composition of claim 1, wherein the carbon backbone of each amino acid moiety independently comprises from 1 to 9 carbon atoms.

3. The treatment composition of claim 1 or 2, wherein the linking group is a divalent organic moiety having from 1 to 18 chain atoms.

4. 3. The treatment composition of claim 1, wherein the two amino acid moieties are covalently linked by a direct single bond.

5. 3. The treatment composition of claim 1, wherein the linking group is derived, at least in part, from at least one side chain of one of the amino acid moieties.

6. 3. The treatment composition of claim 1, wherein at least one of the amino acid moieties is derived from a proteinogenic amino acid.

7. The treatment composition of claim 1 or 2, wherein the two amino acid moieties are derived from amino acids having the same identity.

8. 3. The treating composition of claim 1, wherein both of said amino acid moieties each comprise an organic moiety covalently bonded to the nitrogen atom of said respective amino acid moiety.

9. the one or more hydrophobic moieties are organic groups having a log P of 2.8 to 10.8; the log P is determined for the parent alcohol of the organic group; 3. The processing composition of claim 1, wherein the parent alcohol comprises an alcohol group (-OH) at the position where the organic moiety is covalently bonded to a heteroatom selected from O, S, or N.

10. the one or more hydrophobic moieties include a first hydrophobic moiety and optionally a second hydrophobic moiety; below: (a) at least one of the first hydrophobic moiety and, if present, the second hydrophobic moiety comprises at least five chain atoms; and / or (b) the second hydrophobic moiety is present, and the sum of the number of chain atoms in the first hydrophobic moiety and the second hydrophobic moiety is at least 8; 3. The treatment composition of claim 1, wherein at least one of the following is true:

11. The treatment composition of claim 1 or 2, wherein the one or more hydrophobic moieties are unsubstituted hydrocarbons, unbranched hydrocarbons, or combinations thereof.

12. 1. A treatment composition comprising: a processing aid; and a modified amino acid dimer compound, the modified amino acid dimer compound having Formula I: 【Chemistry 1】 wherein L is a linking group containing 1 to 18 chain atoms, said linking group not containing a peptide bond; each Q is an independently selected carbon-containing core containing 1 to 9 carbon atoms; Each G is independently —O—, —N(R ６ )-, or -S-; R ６ is, when present, selected from —H or a monovalent moiety having a molecular weight of 15 to 255 Da; Each R ３ are independently selected from H, X, or a monovalent organic group having a molecular weight of 15 to 881 Da and a log P of at least 1.3; X is a suitable charge-balancing counterion selected from sodium, potassium, lithium, or ammonium; However, at least one R ３ is the monovalent organic group, R ３ and, if present, R ６ said monovalent moieties together comprise a total of 5 to 34 chain atoms; each A group is a monovalent nitrogen-containing moiety; at least one A group comprises a benefit agent residue that can be cleaved to release the benefit agent; The benefit agent comprises an aldehyde moiety, a ketone moiety, or a combination thereof. A treatment composition characterized by a structure according to

13. Each A group is independently (a)H ２ N-、 (b)Z ＊＊ N-、 (In the formula, ＊＊ represents the connecting bond between the nitrogen atom and the carbon atom of the Z group, said connecting bond being (i) a double bond, thereby forming an imine bond, or (ii) the benefit agent from which the benefit agent residue is derived comprises an α-β unsaturated carbonyl-containing moiety that is an aldehyde moiety or a ketone moiety; and ＊＊ If the nitrogen atom of the N-group is further bonded to a hydrogen (-H), it is one of the single bonds formed from the 1,4-addition. (c) HG'(J) ｄ N(H)-, and (d) 【Chemistry 2】 wherein the subscript d is selected from 1 to 3; Each G' is independently -O-, -S-, or -N(R ７ ) - is selected from the Z group contains 4 to 34 carbon atoms, and the N and the G' are attached to the same carbon atom of the Z group; Each R ７ is, if present, independently selected from —H or a monovalent moiety having a molecular weight of 15 to 255 Da; Each J is independently C(R ９ ) ２ , —O—, and —N(R ９ ) selected from the group consisting of Each R ９ is independently selected from H or a monovalent moiety having a molecular weight of 14 to 990 Da; However, the first R ９ and the second R ９ may optionally, where practicable, be combined as a divalent substituent; R ７ are as defined above, if present) is selected from the group consisting of at least one A group is independently selected from (b) or (d); 13. The treatment composition of claim 12, wherein each Z group is an independently selected benefit agent residue.

14. At least one A group is (b) Z ＊＊ N-, and said Z ＊＊ The Z groups of the N-moiety are independently 【Transformation 3】 (Wherein, the =C(R ４ ) (R ５ ) and —CH(R ８ ) CH ２ C(O)R ５ each of the moieties represents a residue of a benefit agent, said residue of said benefit agent having a molecular formula that differs from said molecular formula of said benefit agent only by having one less O atom or one more H atom, said benefit agent comprising an aldehyde moiety, a ketone moiety, or a combination thereof; R ４ are independently selected from monovalent organic moieties; R ５ and R ８ is independently selected from the group consisting of hydrogen and monovalent organic moieties; However, R ４ and R ５ , or R ８ and R ５ may be linked to form a cyclic divalent organic moiety 14. The treatment composition of claim 12 or 13, selected from the group consisting of: and mixtures thereof.

Images